

MEDICAL CANNABIS AMENDMENTS

2023 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Luz Escamilla

House Sponsor: Raymond P. Ward

LONG TITLE**General Description:**

This bill enacts provisions related to medical cannabis.

Highlighted Provisions:

This bill:

- ▶ defines terms;
- ▶ allows the cannabis research review board to make recommendations to the Department of Agriculture and Food regarding substances found in cannabis products;
- ▶ for the initial issuance of a medical cannabis card, extends the expiration date from six months to one year unless the recommending medical provider provides a shorter expiration date;
- ▶ allows the Department of Health and Human Services to revoke a medical cannabis patient card if the recommending medical provider withdraws the provider's recommendation for medical cannabis;
- ▶ allows certain physician assistants to diagnose post-traumatic stress syndrome for the purpose of recommending medical cannabis;
- ▶ allows medical cannabis pharmacies to maintain a liquid cash account instead of a surety bond;
- ▶ allows the Compassionate Use Board to review the recommendation of a cannabis product that must be vaporized under certain circumstances;



- 28 ▶ allows a recommending medical provider to provide an initial recommendation for
- 29 medical cannabis virtually under certain circumstances;
- 30 ▶ modifies continuing education requirements for qualified medical providers;
- 31 ▶ allows an individual residing in certain care facilities to use an expired license to
- 32 obtain medical cannabis;
- 33 ▶ consolidates certain criminal background check requirements for guardians and
- 34 caregivers;
- 35 ▶ for publicly traded medical cannabis pharmacies, changes the ownership percentage
- 36 an individual must have to be:
 - 37 • listed in an application for a license; or
 - 38 • required to submit a background check;
- 39 ▶ repeals provisions related to the state central patient portal medical provider;
- 40 ▶ authorizes a medical cannabis pharmacy to engage in targeted marketing; and
- 41 ▶ makes technical changes.

42 Money Appropriated in this Bill:

43 None

44 Other Special Clauses:

45 None

46 Utah Code Sections Affected:**47 AMENDS:**

- 48 **26-61-202**, as last amended by Laws of Utah 2022, Chapter 415
- 49 **26-61a-102**, as last amended by Laws of Utah 2022, Chapters 290, 452
- 50 **26-61a-103**, as last amended by Laws of Utah 2022, Chapters 290, 415
- 51 **26-61a-104**, as last amended by Laws of Utah 2022, Chapters 277, 452
- 52 **26-61a-105**, as last amended by Laws of Utah 2022, Chapter 452
- 53 **26-61a-106**, as last amended by Laws of Utah 2022, Chapters 415, 452
- 54 **26-61a-116**, as enacted by Laws of Utah 2022, Chapter 452
- 55 **26-61a-201**, as last amended by Laws of Utah 2022, Chapters 198, 290 and 452
- 56 **26-61a-202**, as last amended by Laws of Utah 2022, Chapters 290, 452
- 57 **26-61a-301**, as last amended by Laws of Utah 2022, Chapter 290
- 58 **26-61a-302**, as last amended by Laws of Utah 2019, First Special Session, Chapter 5

59 **26-61a-403**, as last amended by Laws of Utah 2022, Chapters 415, 452
60 **26-61a-501**, as last amended by Laws of Utah 2022, Chapters 290, 415
61 **26-61a-502**, as last amended by Laws of Utah 2022, Chapter 290
62 **26-61a-503**, as last amended by Laws of Utah 2022, Chapter 415
63 **26-61a-505**, as last amended by Laws of Utah 2022, Chapter 452 and last amended by
64 Coordination Clause, Laws of Utah 2022, Chapter 290
65 **26-61a-506**, as last amended by Laws of Utah 2022, Chapter 415
66 **26-61a-601**, as last amended by Laws of Utah 2021, Chapter 337
67 **26-61a-604**, as last amended by Laws of Utah 2022, Chapters 290, 452
68 **26-61a-606**, as last amended by Laws of Utah 2022, Chapters 290, 415
69 **26-61a-607**, as last amended by Laws of Utah 2022, Chapter 452
70 **58-17b-502**, as last amended by Laws of Utah 2022, Chapter 465
71 **58-67-502**, as last amended by Laws of Utah 2021, Chapter 337
72 **58-68-502**, as last amended by Laws of Utah 2021, Chapter 337
73 **78A-2-231**, as last amended by Laws of Utah 2022, Chapter 256
74 **80-3-110**, as last amended by Laws of Utah 2022, Chapter 256
75 **80-4-109**, as enacted by Laws of Utah 2021, Chapter 261

76 ENACTS:

77 **26-61a-117**, Utah Code Annotated 1953
78 **26-61a-206**, Utah Code Annotated 1953

79 REPEALS:

80 **26-61a-602**, as last amended by Laws of Utah 2020, Chapter 354

81

82 *Be it enacted by the Legislature of the state of Utah:*

83 Section 1. Section **26-61-202** is amended to read:

84 **26-61-202. Duties.**

85 (1) The board shall review any available scientific research related to the human use of
86 cannabis, a cannabinoid product, or an expanded cannabinoid product that:

- 87 (a) was conducted under a study approved by an IRB;
88 (b) was conducted or approved by the federal government; or
89 (c) (i) was conducted in another country; and

(ii) demonstrates, as determined by the board, a sufficient level of scientific reliability and significance to merit the board's review.

(2) Based on the research described in Subsection (1), the board shall evaluate the safety and efficacy of cannabis, cannabinoid products, and expanded cannabinoid products, including:

(a) medical conditions that respond to cannabis, cannabinoid products, and expanded cannabinoid products;

(b) cannabis and cannabinoid dosage amounts and medical dosage forms;

(c) interaction of cannabis, cannabinoid products, and expanded cannabinoid products with other treatments; and

(d) contraindications, adverse reactions, and potential side effects from use of cannabis, cannabinoid products, and expanded cannabinoid products.

(3) (a) Based on the board's evaluation under Subsection (2), the board shall develop guidelines for treatment with cannabis, a cannabinoid product, and an expanded cannabinoid product that include:

~~[(a)]~~ (i) a list of medical conditions, if any, that the board determines are appropriate for treatment with cannabis, a cannabis product, a cannabinoid product, or an expanded cannabinoid product;

~~[(b)]~~ (ii) a list of contraindications, side effects, and adverse reactions that are associated with use of cannabis, cannabinoid products, or expanded cannabinoid products;

~~[(c)]~~ (iii) a list of potential drug-drug interactions between medications that the United States Food and Drug Administration has approved and cannabis, cannabinoid products, and expanded cannabinoid products; and

~~[(d)]~~ (iv) any other guideline the board determines appropriate.

~~[(4)]~~ (b) The board shall submit the guidelines described in Subsection (3) to the director of the Division of Professional Licensing.

~~[(5)]~~ (c) Guidelines that the board develops under this section may not limit the availability of cannabis, cannabinoid products, or expanded cannabinoid products permitted under Title 4, Chapter 41a, Cannabis Production Establishments, or Title 26, Chapter 61a, Utah Medical Cannabis Act.

(4) The board shall provide a report to the Health and Human Services Interim

121 Committee regarding the board's work before October 1 of each year.

122 Section 2. Section **26-61a-102** is amended to read:

123 **26-61a-102. Definitions.**

124 As used in this chapter:

125 (1) "Active tetrahydrocannabinol" means THC, any THC analog, and
126 tetrahydrocannabinolic acid.

127 (2) "Cannabis Research Review Board" means the Cannabis Research Review Board
128 created in Section **26-61-201**.

129 (3) "Cannabis" means marijuana.

130 (4) "Cannabis cultivation facility" means the same as that term is defined in Section
131 **4-41a-102**.

132 (5) "Cannabis processing facility" means the same as that term is defined in Section
133 **4-41a-102**.

134 (6) "Cannabis product" means a product that:

135 (a) is intended for human use; and

136 (b) contains cannabis or any tetrahydrocannabinol or THC analog in a total
137 concentration of 0.3% or greater on a dry weight basis.

138 (7) "Cannabis production establishment" means the same as that term is defined in
139 Section **4-41a-102**.

140 (8) "Cannabis production establishment agent" means the same as that term is defined
141 in Section **4-41a-102**.

142 (9) "Cannabis production establishment agent registration card" means the same as that
143 term is defined in Section **4-41a-102**.

144 (10) "Community location" means a public or private elementary or secondary school,
145 a church, a public library, a public playground, or a public park.

146 (11) "Conditional medical cannabis card" means an electronic medical cannabis card
147 that the department issues in accordance with Subsection **26-61a-201(1)(b)** to allow an
148 applicant for a medical cannabis card to access medical cannabis during the department's
149 review of the application.

150 (12) "Controlled substance database" means the controlled substance database created
151 in Section **58-37f-201**.

152 (13) "Delivery address" means:

153 (a) for a medical cannabis cardholder who is not a facility, the medical cannabis
154 cardholder's home address; or

155 (b) for a medical cannabis cardholder that is a facility, the facility's address.

156 ~~[(13)]~~ (14) "Department" means the Department of Health.

157 ~~[(14)]~~ (15) "Designated caregiver" means:

158 (a) an individual:

159 (i) whom an individual with a medical cannabis patient card or a medical cannabis
160 guardian card designates as the patient's caregiver; and

161 (ii) who registers with the department under Section 26-61a-202; or

162 (b) (i) a facility that an individual designates as a designated caregiver in accordance
163 with Subsection 26-61a-202(1)(b); or

164 (ii) an assigned employee of the facility described in Subsection 26-61a-202(1)(b)(ii).

165 ~~[(15)]~~ (16) "Directions of use" means recommended routes of administration for a
166 medical cannabis treatment and suggested usage guidelines.

167 ~~[(16)]~~ (17) "Dosing guidelines" means a quantity range and frequency of administration
168 for a recommended treatment of medical cannabis.

169 ~~[(17)]~~ (18) "Financial institution" means a bank, trust company, savings institution, or
170 credit union, chartered and supervised under state or federal law.

171 (19) "Government issued photo identification" means any of the following forms of
172 identification:

173 (a) a valid state-issued driver license or identification card;

174 (b) a valid United States federal-issued photo identification, including:

175 (i) a United States passport;

176 (ii) a United States passport card;

177 (iii) a United States military identification card; or

178 (iv) a permanent resident card or alien registration receipt card; or

179 (c) a foreign passport.

180 ~~[(18)]~~ (20) "Home delivery medical cannabis pharmacy" means a medical cannabis
181 pharmacy that the department authorizes, as part of the pharmacy's license, to deliver medical
182 cannabis shipments to a ~~[medical cannabis cardholder's home address]~~ delivery address to

fulfill electronic orders that the state central patient portal facilitates.

~~[(19)]~~ (21) "Inventory control system" means the system described in Section 4-41a-103.

~~[(20)]~~ (22) "Legal dosage limit" means an amount that:

(a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the relevant recommending medical provider or the state central patient portal or pharmacy medical provider, in accordance with Subsection 26-61a-502(4) ~~[or (5)]~~, recommends; and

(b) may not exceed:

(i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and

(ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in total, greater than 20 grams of active tetrahydrocannabinol.

~~[(21)]~~ (23) "Legal use termination date" means a date on the label of a container of unprocessed cannabis flower:

(a) that is 60 days after the date of purchase of the cannabis; and

(b) after which, the cannabis is no longer in a medicinal dosage form outside of the primary residence of the relevant medical cannabis patient cardholder.

~~[(22)]~~ (24) "Limited medical provider" means an individual who:

(a) meets the recommending qualifications; and

(b) has no more than 15 patients with a valid medical cannabis patient card or provisional patient card as a result of the individual's recommendation, in accordance with Subsection 26-61a-106(1)(b).

~~[(23)]~~ (25) "Marijuana" means the same as that term is defined in Section 58-37-2.

~~[(24)]~~ (26) "Medical cannabis" means cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form.

~~[(25)]~~ (27) "Medical cannabis card" means a medical cannabis patient card, a medical cannabis guardian card, a medical cannabis caregiver card, or a conditional medical cannabis card.

~~[(26)]~~ (28) "Medical cannabis cardholder" means:

(a) a holder of a medical cannabis card; or

(b) a facility or assigned employee, described in Subsection ~~[(14)(b);~~ (15)(b), only:

(i) within the scope of the facility's or assigned employee's performance of the role of a

medical cannabis patient cardholder's caregiver designation under Subsection
26-61a-202(1)(b); and

(ii) while in possession of documentation that establishes:

(A) a caregiver designation described in Subsection 26-61a-202(1)(b);

(B) the identity of the individual presenting the documentation; and

(C) the relation of the individual presenting the documentation to the caregiver
designation.

~~[(27)]~~ (29) "Medical cannabis caregiver card" means an electronic document that a
cardholder may print or store on an electronic device or a physical card or document that:

(a) the department issues to an individual whom a medical cannabis patient cardholder
or a medical cannabis guardian cardholder designates as a designated caregiver; and

(b) is connected to the electronic verification system.

~~[(28)]~~ (30) "Medical cannabis courier" means a courier that:

(a) the department licenses in accordance with Section 26-61a-604; and

(b) contracts with a home delivery medical cannabis pharmacy to deliver medical
cannabis shipments to fulfill electronic orders that the state central patient portal facilitates.

~~[(29)]~~ (31) "Medical cannabis courier agent" means an individual who:

(a) is an employee of a medical cannabis courier; and

(b) who holds a valid medical cannabis courier agent registration card.

~~[(30)]~~ (32) (a) "Medical cannabis device" means a device that an individual uses to
ingest or inhale cannabis in a medicinal dosage form or a cannabis product in a medicinal
dosage form.

(b) "Medical cannabis device" does not include a device that:

(i) facilitates cannabis combustion; or

(ii) an individual uses to ingest substances other than cannabis.

~~[(31)]~~ (33) "Medical cannabis guardian card" means an electronic document that a
cardholder may print or store on an electronic device or a physical card or document that:

(a) the department issues to the parent or legal guardian of a minor with a qualifying
condition; and

(b) is connected to the electronic verification system.

~~[(32)]~~ (34) "Medical cannabis patient card" means an electronic document that a

cardholder may print or store on an electronic device or a physical card or document that:

(a) the department issues to an individual with a qualifying condition; and

(b) is connected to the electronic verification system.

~~[(33)]~~ (35) "Medical cannabis pharmacy" means a person that:

(a) (i) acquires or intends to acquire medical cannabis or a cannabis product in a medicinal dosage form from a cannabis processing facility or another medical cannabis pharmacy or a medical cannabis device; or

(ii) possesses medical cannabis or a medical cannabis device; and

(b) sells or intends to sell medical cannabis or a medical cannabis device to a medical cannabis cardholder.

~~[(34)]~~ (36) "Medical cannabis pharmacy agent" means an individual who:

(a) is an employee of a medical cannabis pharmacy; and

(b) who holds a valid medical cannabis pharmacy agent registration card.

~~[(35)]~~ (37) "Medical cannabis pharmacy agent registration card" means a registration card issued by the department that authorizes an individual to act as a medical cannabis pharmacy agent.

~~[(36)]~~ (38) "Medical cannabis shipment" means a shipment of medical cannabis or a medical cannabis product that a home delivery medical cannabis pharmacy or a medical cannabis courier delivers to a ~~[medical cannabis cardholder's home address]~~ delivery address to fulfill an electronic medical cannabis order that the state central patient portal facilitates.

~~[(37)]~~ (39) "Medical cannabis treatment" means cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device.

~~[(38)]~~ (40) (a) "Medicinal dosage form" means:

(i) for processed medical cannabis or a medical cannabis product, the following with a specific and consistent cannabinoid content:

(A) a tablet;

(B) a capsule;

(C) a concentrated liquid or viscous oil;

(D) a liquid suspension that, after December 1, 2022, does not exceed 30 ml;

(E) a topical preparation;

(F) a transdermal preparation;

276 (G) a sublingual preparation;

277 (H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or
278 rectangular cuboid shape;

279 (I) a resin or wax; or

280 (J) an aerosol; or

281 (ii) for unprocessed cannabis flower, a container described in Section 4-41a-602 that:

282 (A) contains cannabis flowers in a quantity that varies by no more than 10% from the
283 stated weight at the time of packaging;

284 (B) at any time the medical cannabis cardholder transports or possesses the container in
285 public, is contained within an opaque bag or box that the medical cannabis pharmacy provides;
286 and

287 (C) is labeled with the container's content and weight, the date of purchase, the legal
288 use termination date, and after December 31, 2020, a barcode that provides information
289 connected to an inventory control system; and

290 (iii) a form measured in grams, milligrams, or milliliters.

291 (b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:

292 (i) the medical cannabis cardholder has recently removed from the container described
293 in Subsection ~~[(38)]~~ (40)(a)(ii) for use; and

294 (ii) does not exceed the quantity described in Subsection ~~[(38)]~~ (40)(a)(ii).

295 (c) "Medicinal dosage form" does not include:

296 (i) any unprocessed cannabis flower outside of the container described in Subsection
297 ~~[(38)]~~ (40)(a)(ii), except as provided in Subsection ~~[(38)]~~ (40)(b);

298 (ii) any unprocessed cannabis flower in a container described in Subsection ~~[(38)]~~
299 (40)(a)(ii) after the legal use termination date;

300 (iii) a process of vaporizing and inhaling concentrated cannabis by placing the cannabis
301 on a nail or other metal object that is heated by a flame, including a blowtorch; or

302 (iv) a liquid suspension that is branded as a beverage.

303 ~~[(39)]~~ (41) "Nonresident patient" means an individual who:

304 (a) is not a resident of Utah or has been a resident of Utah for less than 45 days;

305 (b) has a currently valid medical cannabis card or the equivalent of a medical cannabis
306 card under the laws of another state, district, territory, commonwealth, or insular possession of

the United States; and

(c) has been diagnosed with a qualifying condition as described in Section 26-61a-104.

~~[(40)]~~ (42) "Payment provider" means an entity that contracts with a cannabis production establishment or medical cannabis pharmacy to facilitate transfers of funds between the establishment or pharmacy and other businesses or individuals.

~~[(41)]~~ (43) "Pharmacy medical provider" means the medical provider required to be on site at a medical cannabis pharmacy under Section 26-61a-403.

~~[(42)]~~ (44) "Provisional patient card" means a card that:

(a) the department issues to a minor with a qualifying condition for whom:

(i) a recommending medical provider has recommended a medical cannabis treatment;

and

(ii) the department issues a medical cannabis guardian card to the minor's parent or legal guardian; and

(b) is connected to the electronic verification system.

~~[(43)]~~ (45) "Qualified medical provider" means an individual:

(a) who meets the recommending qualifications; and

(b) whom the department registers to recommend treatment with cannabis in a medicinal dosage form under Section 26-61a-106.

~~[(44)]~~ (46) "Qualified Patient Enterprise Fund" means the enterprise fund created in Section 26-61a-109.

~~[(45)]~~ (47) "Qualifying condition" means a condition described in Section 26-61a-104.

~~[(46)]~~ (48) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which:

(a) certifies the patient's eligibility for a medical cannabis card; and

(b) may include, at the recommending medical provider's discretion, directions of use, with or without dosing guidelines.

~~[(47)]~~ (49) "Recommending medical provider" means a qualified medical provider or a limited medical provider.

~~[(48)]~~ (50) "Recommending qualifications" means that an individual:

(a) (i) has the authority to write a prescription;

(ii) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah

Controlled Substances Act; and

(iii) possesses the authority, in accordance with the individual's scope of practice, to prescribe a Schedule II controlled substance; and

(b) is licensed as:

(i) a podiatrist under Title 58, Chapter 5a, Podiatric Physician Licensing Act;

(ii) an advanced practice registered nurse under Title 58, Chapter 31b, Nurse Practice Act;

(iii) a physician under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or

(iv) a physician assistant under Title 58, Chapter 70a, Utah Physician Assistant Act.

~~[(49)]~~ (51) "State central patient portal" means the website the department creates, in accordance with Section ~~26-61a-601~~, to facilitate patient safety, education, and an electronic medical cannabis order.

~~[(50)] "State central patient portal medical provider" means a physician or pharmacist that the department employs in relation to the state central patient portal to consult with medical cannabis cardholders in accordance with Section 26-61a-602.]~~

~~[(51)]~~ (52) "State electronic verification system" means the system described in Section ~~26-61a-103~~.

~~[(52)]~~ (53) "Tetrahydrocannabinol" or "THC" means a substance derived from cannabis or a synthetic equivalent as described in Subsection ~~58-37-4(2)(a)(iii)(AA)~~.

~~[(53)]~~ (54) "THC analog" means the same as that term is defined in Section ~~4-41-102~~.

~~[(54)] "Valid form of photo identification" means any of the following forms of identification that is either current or has expired within the previous six months:]~~

~~[(a) a valid state-issued driver license or identification card;]~~

~~[(b) a valid United States federal-issued photo identification, including:]~~

~~[(i) a United States passport;]~~

~~[(ii) a United States passport card;]~~

~~[(iii) a United States military identification card; or]~~

~~[(iv) a permanent resident card or alien registration receipt card; or]~~

~~[(c) a passport that another country issued.]~~

Section 3. Section ~~26-61a-103~~ is amended to read:

26-61a-103. Electronic verification system.

(1) The Department of Agriculture and Food, the department, the Department of Public Safety, and the Division of Technology Services shall:

(a) enter into a memorandum of understanding in order to determine the function and operation of the state electronic verification system in accordance with Subsection (2);

(b) coordinate with the Division of Purchasing, under Title 63G, Chapter 6a, Utah Procurement Code, to develop a request for proposals for a third-party provider to develop and maintain the state electronic verification system in coordination with the Division of Technology Services; and

(c) select a third-party provider who:

(i) meets the requirements contained in the request for proposals issued under Subsection (1)(b); and

(ii) may not have any commercial or ownership interest in a cannabis production establishment or a medical cannabis pharmacy.

(2) The Department of Agriculture and Food, the department, the Department of Public Safety, and the Division of Technology Services shall ensure that~~[-, on or before March 1, 2020,~~]the state electronic verification system described in Subsection (1):

(a) allows an individual to apply for a medical cannabis patient card or, if applicable, a medical cannabis guardian card, provided that the card may not become active until:

(i) the relevant qualified medical provider completes the associated medical cannabis recommendation; or

(ii) for a medical cannabis card related to a limited medical provider's recommendation, the medical cannabis pharmacy completes the recording described in Subsection (2)(d);

(b) allows an individual to apply to renew a medical cannabis patient card or a medical cannabis guardian card in accordance with Section 26-61a-201;

(c) allows a qualified medical provider, or an employee described in Subsection (3) acting on behalf of the qualified medical provider, to:

(i) access dispensing and card status information regarding a patient:

(A) with whom the qualified medical provider has a provider-patient relationship; and

(B) for whom the qualified medical provider has recommended or is considering

recommending a medical cannabis card;

(ii) electronically recommend~~[-, after an initial face-to-face visit with a patient described in Subsection 26-61a-201(4)(a)(iii),]~~ treatment with cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form and optionally recommend dosing guidelines; ~~[and]~~

(iii) electronically renew a recommendation to a medical cannabis patient cardholder or medical cannabis guardian cardholder:

(A) using telehealth services, for the qualified medical provider who originally recommended a medical cannabis treatment during a face-to-face visit with the patient; or

(B) during a face-to-face visit with the patient, for a qualified medical provider who did not originally recommend the medical cannabis treatment during a face-to-face visit~~[-]; and~~

(iv) submit an initial application, renewal application, or application payment on behalf of an individual applying for any of the following:

(A) a medical cannabis patient card;

(B) a medical cannabis guardian card; or

(C) a medical cannabis caregiver card;

(d) ~~[beginning on the earlier of September 1, 2021, or the date on which the electronic verification system is functionally capable of facility medical cannabis pharmacy recording,]~~ allows a medical cannabis pharmacy medical provider or medical cannabis pharmacy agent, in accordance with Subsection 26-61a-501(10)(a), to:

(i) access the electronic verification system to review the history within the system of a patient with whom the provider or agent is interacting, limited to read-only access for medical cannabis pharmacy agents unless the medical cannabis pharmacy's pharmacist in charge authorizes add and edit access;

(ii) record a patient's recommendation from a limited medical provider, including any directions of use, dosing guidelines, or caregiver indications from the limited medical provider; ~~[and]~~

(iii) record a limited medical provider's renewal of the provider's previous recommendation; and

(iv) submit an initial application, renewal application, or application payment on behalf of an individual applying for any of the following:

431 (A) a medical cannabis patient card;

432 (B) a medical cannabis guardian card; or

433 (C) a medical cannabis caregiver card;

434 (e) connects with:

435 (i) an inventory control system that a medical cannabis pharmacy uses to track in real
436 time and archive purchases of any cannabis in a medicinal dosage form, cannabis product in a
437 medicinal dosage form, or a medical cannabis device, including:

438 (A) the time and date of each purchase;

439 (B) the quantity and type of cannabis, cannabis product, or medical cannabis device
440 purchased;

441 (C) any cannabis production establishment, any medical cannabis pharmacy, or any
442 medical cannabis courier associated with the cannabis, cannabis product, or medical cannabis
443 device; and

444 (D) the personally identifiable information of the medical cannabis cardholder who
445 made the purchase; and

446 (ii) any commercially available inventory control system that a cannabis production
447 establishment utilizes in accordance with Section 4-41a-103 to use data that the Department of
448 Agriculture and Food requires by rule, in accordance with Title 63G, Chapter 3, Utah
449 Administrative Rulemaking Act, from the inventory tracking system that a licensee uses to
450 track and confirm compliance;

451 (f) provides access to:

452 (i) the department to the extent necessary to carry out the department's functions and
453 responsibilities under this chapter;

454 (ii) the Department of Agriculture and Food to the extent necessary to carry out the
455 functions and responsibilities of the Department of Agriculture and Food under Title 4, Chapter
456 41a, Cannabis Production Establishments; and

457 (iii) the Division of Professional Licensing to the extent necessary to carry out the
458 functions and responsibilities related to the participation of the following in the
459 recommendation and dispensing of medical cannabis:

460 (A) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;

461 (B) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;

(C) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse Practice Act;

(D) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or

(E) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant Act;

(g) provides access to and interaction with the state central patient portal;

(h) communicates dispensing information from a record that a medical cannabis pharmacy submits to the state electronic verification system under Subsection ~~[26-61a-502(6)(a)(ii)]~~ 26-61a-502(5)(a)(ii) to the controlled substance database;

(i) provides access to state or local law enforcement:

(i) during a law enforcement encounter, without a warrant, using the individual's driver license or state ID, only for the purpose of determining if the individual subject to the law enforcement encounter has a valid medical cannabis card; or

(ii) after obtaining a warrant; and

(j) creates a record each time a person accesses the system that identifies the person who accesses the system and the individual whose records the person accesses.

(3) (a) ~~[Beginning on the earlier of September 1, 2021, or the date on which the electronic verification system is functionally capable of allowing employee access under this Subsection (3), an]~~ An employee of a qualified medical provider may access the electronic verification system for a purpose described in Subsection (2)(c) on behalf of the qualified medical provider if:

(i) the qualified medical provider has designated the employee as an individual authorized to access the electronic verification system on behalf of the qualified medical provider;

(ii) the qualified medical provider provides written notice to the department of the employee's identity and the designation described in Subsection (3)(a)(i); and

(iii) the department grants to the employee access to the electronic verification system.

(b) An employee of a business that employs a qualified medical provider may access the electronic verification system for a purpose described in Subsection (2)(c) on behalf of the qualified medical provider if:

(i) the qualified medical provider has designated the employee as an individual authorized to access the electronic verification system on behalf of the qualified medical provider;

(ii) the qualified medical provider and the employing business jointly provide written notice to the department of the employee's identity and the designation described in Subsection (3)(b)(i); and

(iii) the department grants to the employee access to the electronic verification system.

(4) (a) As used in this Subsection (4), "prescribing provider" means:

(i) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;

(ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse Practice Act;

(iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or

(iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant Act.

~~(b) [Beginning on the earlier of September 1, 2021, or the date on which the electronic verification system is functionally capable of allowing provider access under this Subsection (4), a]~~ A prescribing provider may access information in the electronic verification system regarding a patient the prescribing provider treats.

(5) The department may release limited data that the system collects for the purpose of:

(a) conducting medical and other department approved research;

(b) providing the report required by Section 26-61a-703; and

(c) other official department purposes.

(6) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to establish:

(a) the limitations on access to the data in the state electronic verification system as described in this section; and

(b) standards and procedures to ensure accurate identification of an individual requesting information or receiving information in this section.

(7) (a) Any person who knowingly and intentionally releases any information in the state electronic verification system in violation of this section is guilty of a third degree felony.

(b) Any person who negligently or recklessly releases any information in the state electronic verification system in violation of this section is guilty of a class C misdemeanor.

(8) (a) Any person who obtains or attempts to obtain information from the state electronic verification system by misrepresentation or fraud is guilty of a third degree felony.

(b) Any person who obtains or attempts to obtain information from the state electronic verification system for a purpose other than a purpose this chapter authorizes is guilty of a third degree felony.

(9) (a) Except as provided in Subsection (9)(e), a person may not knowingly and intentionally use, release, publish, or otherwise make available to any other person information obtained from the state electronic verification system for any purpose other than a purpose specified in this section.

(b) Each separate violation of this Subsection (9) is:

(i) a third degree felony; and

(ii) subject to a civil penalty not to exceed \$5,000.

(c) The department shall determine a civil violation of this Subsection (9) in accordance with Title 63G, Chapter 4, Administrative Procedures Act.

(d) Civil penalties assessed under this Subsection (9) shall be deposited into the General Fund.

(e) This Subsection (9) does not prohibit a person who obtains information from the state electronic verification system under Subsection (2)(a), (c), or (f) from:

(i) including the information in the person's medical chart or file for access by a person authorized to review the medical chart or file;

(ii) providing the information to a person in accordance with the requirements of the Health Insurance Portability and Accountability Act of 1996; or

(iii) discussing or sharing that information about the patient with the patient.

Section 4. Section **26-61a-104** is amended to read:

26-61a-104. Qualifying condition.

(1) By designating a particular condition under Subsection (2) for which the use of medical cannabis to treat symptoms is decriminalized, the Legislature does not conclusively state that:

(a) current scientific evidence clearly supports the efficacy of a medical cannabis

555 treatment for the condition; or

556 (b) a medical cannabis treatment will treat, cure, or positively affect the condition.

557 (2) For the purposes of this chapter, each of the following conditions is a qualifying
558 condition:

559 (a) HIV or acquired immune deficiency syndrome;

560 (b) Alzheimer's disease;

561 (c) amyotrophic lateral sclerosis;

562 (d) cancer;

563 (e) cachexia;

564 (f) persistent nausea that is not significantly responsive to traditional treatment, except
565 for nausea related to:

566 (i) pregnancy;

567 (ii) cannabis-induced cyclical vomiting syndrome; or

568 (iii) cannabinoid hyperemesis syndrome;

569 (g) Crohn's disease or ulcerative colitis;

570 (h) epilepsy or debilitating seizures;

571 (i) multiple sclerosis or persistent and debilitating muscle spasms;

572 (j) post-traumatic stress disorder that is being treated and monitored by a licensed
573 mental health therapist, as that term is defined in Section 58-60-102, and that:

574 (i) has been diagnosed by a healthcare provider or mental health provider employed or
575 contracted by the United States Veterans Administration, evidenced by copies of medical
576 records from the United States Veterans Administration that are included as part of the
577 qualified medical provider's pre-treatment assessment and medical record documentation; or

578 (ii) has been diagnosed or confirmed, through face-to-face or telehealth evaluation of
579 the patient, by a provider who is:

580 (A) a licensed board-eligible or board-certified psychiatrist;

581 (B) a licensed psychologist with a master's-level degree;

582 (C) a licensed clinical social worker with a master's-level degree; [or]

583 (D) a licensed advanced practice registered nurse who is qualified to practice within
584 the psychiatric mental health nursing specialty and who has completed the clinical practice
585 requirements in psychiatric mental health nursing, including in psychotherapy, in accordance

with Subsection [58-31b-302\(5\)\(g\)](#); or

(E) a licensed physician assistant who is qualified to specialize in mental health care under Section [58-70a-501.1](#);

(k) autism;

(l) a terminal illness when the patient's remaining life expectancy is less than six months;

(m) a condition resulting in the individual receiving hospice care;

(n) a rare condition or disease that:

(i) affects less than 200,000 individuals in the United States, as defined in Section 526 of the Federal Food, Drug, and Cosmetic Act; and

(ii) is not adequately managed despite treatment attempts using:

(A) conventional medications other than opioids or opiates; or

(B) physical interventions;

(o) pain lasting longer than two weeks that is not adequately managed, in the qualified medical provider's opinion, despite treatment attempts using:

(i) conventional medications other than opioids or opiates; or

(ii) physical interventions;

(p) pain that is expected to last for two weeks or longer for an acute condition, including a surgical procedure, for which a medical professional may generally prescribe opioids for a limited duration, subject to Subsection [26-61a-201\(5\)\(c\)](#); and

(q) a condition that the Compassionate Use Board approves under Section [26-61a-105](#), on an individual, case-by-case basis.

Section 5. Section **26-61a-105** is amended to read:

26-61a-105. Compassionate Use Board.

(1) (a) The department shall establish a Compassionate Use Board consisting of:

(i) seven qualified medical providers that the executive director appoints and the Senate confirms:

(A) who are knowledgeable about the medicinal use of cannabis;

(B) who are physicians licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and

(C) ~~[whom the appropriate board certifies]~~ who are board certified by the American

Board of Medical Specialties in the specialty of neurology, pain medicine and pain management, medical oncology, psychiatry, infectious disease, internal medicine, pediatrics, family medicine, or gastroenterology; and

(ii) as a nonvoting member and the chair of the Compassionate Use Board, the executive director or the director's designee.

(b) In appointing the seven qualified medical providers described in Subsection (1)(a), the executive director shall ensure that at least two have a board certification in pediatrics.

(2) (a) Of the members of the Compassionate Use Board that the executive director first appoints:

(i) three shall serve an initial term of two years; and

(ii) the remaining members shall serve an initial term of four years.

(b) After an initial term described in Subsection (2)(a) expires:

(i) each term is four years; and

(ii) each board member is eligible for reappointment.

(c) A member of the Compassionate Use Board may serve until a successor is appointed.

(3) Four members constitute a quorum of the Compassionate Use Board.

(4) A member of the Compassionate Use Board may receive:

(a) notwithstanding Section 63A-3-106, compensation or benefits for the member's service; and

(b) travel expenses in accordance with Section 63A-3-107 and rules made by the Division of Finance in accordance with Section 63A-3-107.

(5) The Compassionate Use Board shall:

(a) review and recommend for department approval a petition to the board regarding an individual described in Subsection 26-61a-201(2)(a), a minor described in Subsection 26-61a-201(2)(c), or an individual who is not otherwise qualified to receive a medical cannabis card to obtain a medical cannabis card for compassionate use, for the standard or a reduced period of validity, if:

(i) for an individual who is not otherwise qualified to receive a medical cannabis card, the individual's qualified medical provider is actively treating the individual for an intractable condition that:

648 (A) substantially impairs the individual's quality of life; and
649 (B) has not, in the qualified medical provider's professional opinion, adequately
650 responded to conventional treatments;

651 (ii) the qualified medical provider:

652 (A) recommends that the individual or minor be allowed to use medical cannabis; and
653 (B) provides a letter, relevant treatment history, and notes or copies of progress notes
654 describing relevant treatment history including rationale for considering the use of medical
655 cannabis; and

656 (iii) the Compassionate Use Board determines that:

657 (A) the recommendation of the individual's qualified medical provider is justified; and
658 (B) based on available information, it may be in the best interests of the individual to
659 allow the use of medical cannabis;

660 (b) ~~[review and approve or deny the use of a medical cannabis device for an individual~~
661 ~~described in Subsection 26-61a-201(2)(a)(i)(B) or a minor described in Subsection~~
662 ~~26-61a-201(2)(c) if the individual's or minor's qualified medical provider recommends that the~~
663 ~~individual or minor be allowed to use a medical cannabis device to vaporize the medical~~
664 ~~cannabis treatment;]~~ when a qualified medical provider recommends that an individual
665 described in Subsection 26-61a-201(2)(a)(i)(B) or a minor described in Subsection
666 26-61a-201(2)(c) be allowed to use a medical cannabis device or medical cannabis product to
667 vaporize a medical cannabis treatment, review and approve or deny the use of the medical
668 cannabis device or medical cannabis product;

669 (c) unless no petitions are pending:

670 (i) meet to receive or review compassionate use petitions at least quarterly; and
671 (ii) if there are more petitions than the board can receive or review during the board's
672 regular schedule, as often as necessary;

673 (d) except as provided in Subsection (6), complete a review of each petition and
674 recommend to the department approval or denial of the applicant for qualification for a medical
675 cannabis card within 90 days after the day on which the board received the petition;

676 (e) consult with the department regarding the criteria described in Subsection (6); and
677 (f) report, before November 1 of each year, to the Health and Human Services Interim
678 Committee:

(i) the number of compassionate use recommendations the board issued during the past year; and

(ii) the types of conditions for which the board recommended compassionate use.

(6) The department shall make rules, in consultation with the Compassionate Use Board and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to establish a process and criteria for a petition to the board to automatically qualify for expedited final review and approval or denial by the department in cases where, in the determination of the department and the board:

(a) time is of the essence;

(b) engaging the full review process would be unreasonable in light of the petitioner's physical condition; and

(c) sufficient factors are present regarding the petitioner's safety.

(7) (a) (i) The department shall review:

(A) any compassionate use for which the Compassionate Use Board recommends approval under Subsection (5)(d) to determine whether the board properly exercised the board's discretion under this section; and

(B) any expedited petitions the department receives under the process described in Subsection (6).

(ii) If the department determines that the Compassionate Use Board properly exercised the board's discretion in recommending approval under Subsection (5)(d) or that the expedited petition merits approval based on the criteria established in accordance with Subsection (6), the department shall:

(A) issue the relevant medical cannabis card; and

(B) provide for the renewal of the medical cannabis card in accordance with the recommendation of the qualified medical provider described in Subsection (5)(a).

(b) (i) If the Compassionate Use Board recommends denial under Subsection (5)(d), the individual seeking to obtain a medical cannabis card may petition the department to review the board's decision.

(ii) If the department determines that the Compassionate Use Board's recommendation for denial under Subsection (5)(d) was arbitrary or capricious:

(A) the department shall notify the Compassionate Use Board of the department's

determination; and

(B) the board shall reconsider the Compassionate Use Board's refusal to recommend approval under this section.

(c) In reviewing the Compassionate Use Board's recommendation for approval or denial under Subsection (5)(d) in accordance with this Subsection (7), the department shall presume the board properly exercised the board's discretion unless the department determines that the board's recommendation was arbitrary or capricious.

(8) Any individually identifiable health information contained in a petition that the Compassionate Use Board or department receives under this section is a protected record in accordance with Title 63G, Chapter 2, Government Records Access and Management Act.

(9) The Compassionate Use Board shall annually report the board's activity to the Cannabis Research Review Board.

Section 6. Section **26-61a-106** is amended to read:

26-61a-106. Qualified medical provider registration -- Continuing education -- Treatment recommendation -- Limited medical provider.

(1) (a) (i) Except as provided in Subsection (1)(b), an individual may not recommend a medical cannabis treatment unless the department registers the individual as a qualified medical provider in accordance with this section.

(ii) Notwithstanding Subsection (1)(a)(i), a qualified medical provider who is podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act, may not recommend a medical cannabis treatment except within the course and scope of a practice of podiatry, as that term is defined in Section **58-5a-102**.

(b) ~~[Beginning on the earlier of September 1, 2021, or the date on which the department gives notice that the electronic verification system is functionally capable as described in Subsection **26-61a-103**(2)(d), an]~~ An individual who meets the recommending qualifications may recommend a medical cannabis treatment as a limited medical provider without registering under Subsection (1)(a) if:

(i) the individual recommends the use of medical cannabis to the patient through an order described in Subsection (1)(c) after:

(A) a face-to-face visit for an initial recommendation or the renewal of a recommendation for a patient for whom the limited medical provider did not make the patient's

original recommendation; or

(B) a visit using telehealth services for a renewal of a recommendation for a patient for whom the limited medical provider made the patient's original recommendation; and

(ii) the individual's recommendation or renewal would not cause the total number of the individual's patients who have a valid medical cannabis patient card or provisional patient card resulting from the individual's recommendation to exceed 15.

(c) The individual described in Subsection (1)(b) shall communicate the individual's recommendation through an order for the medical cannabis pharmacy to record the individual's recommendation or renewal in the state electronic verification system under the individual's recommendation that:

(i) (A) that the individual or the individual's employee sends electronically to a medical cannabis pharmacy; or

(B) that the individual gives to the patient in writing for the patient to deliver to a medical cannabis pharmacy; and

(ii) may include:

(A) directions of use or dosing guidelines; and

(B) an indication of a need for a caregiver in accordance with Subsection 26-61a-201(3)(c).

(d) If the limited medical provider gives the patient a written recommendation to deliver to a medical cannabis pharmacy under Subsection (1)(c)(i)(B), the limited medical provider shall ensure that the document includes all of the information that is included on a prescription the provider would issue for a controlled substance, including:

(i) the date of issuance;

(ii) the provider's name, address and contact information, controlled substance license information, and signature; and

(iii) the patient's name, address and contact information, age, and diagnosed qualifying condition.

(e) In considering making a recommendation as a limited medical provider, an individual may consult information that the department makes available on the department's website for recommending providers.

(2) (a) The department shall, within 15 days after the day on which the department

receives an application from an individual, register and issue a qualified medical provider registration card to the individual if the individual:

(i) provides to the department the individual's name and address;

(ii) provides to the department ~~[a report detailing the individual's completion of the]~~
~~[applicable continuing education requirement described in Subsection (3)]~~ an acknowledgment
that the individual has completed four hours of continuing education related to medical
cannabis;

(iii) provides to the department evidence that the individual meets the recommending qualifications;

(iv) for an applicant on or after November 1, 2021, provides to the department the information described in Subsection (10)(a); and

(v) pays the department a fee in an amount that:

(A) the department sets, in accordance with Section 63J-1-504; and

(B) does not exceed \$300 for an initial registration.

(b) The department may not register an individual as a qualified medical provider if the individual is:

(i) a pharmacy medical provider; or

(ii) an owner, officer, director, board member, employee, or agent of a cannabis production establishment, a medical cannabis pharmacy, or a medical cannabis courier.

(3) (a) An individual shall complete the continuing education ~~[described in this Subsection (3)]~~ related to medical cannabis in the following amounts:

(i) for an individual as a condition precedent to registration, four hours; and

(ii) for a qualified medical provider as a condition precedent to renewal, four hours every two years.

~~[(b) In accordance with Subsection (3)(a), a qualified medical provider shall:]~~

~~[(i) complete continuing education:]~~

~~[(A) regarding the topics described in Subsection (3)(d); and]~~

~~[(B) offered by the department under Subsection (3)(e) or an accredited or approved continuing education provider that the department recognizes as offering continuing education appropriate for the recommendation of cannabis to patients; and]~~

~~[(ii) make a continuing education report to the department in accordance with a process~~

that the department establishes by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, and in collaboration with the Division of Professional Licensing and:]

~~[(A) for a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act, the Podiatric Physician Board;]~~

~~[(B) for an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse Practice Act, the Board of Nursing;]~~

~~[(C) for a qualified medical provider licensed under Title 58, Chapter 67, Utah Medical Practice Act, the Physicians Licensing Board;]~~

~~[(D) for a qualified medical provider licensed under Title 58, Chapter 68, Utah Osteopathic Medical Practice Act, the Osteopathic Physician and Surgeon's Licensing Board; and]~~

~~[(E) for a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant Act, the Physician Assistant Licensing Board;]~~

~~[(c)]~~ (b) The department may, in consultation with the Division of Professional Licensing, develop ~~[the]~~ continuing education ~~[described in this Subsection (3)]~~ related to medical cannabis.

~~[(d)]~~ (c) The continuing education described in this Subsection (3) may discuss:

- (i) the provisions of this chapter;
- (ii) general information about medical cannabis under federal and state law;
- (iii) the latest scientific research on the endocannabinoid system and medical cannabis, including risks and benefits;
- (iv) recommendations for medical cannabis as it relates to the continuing care of a patient in pain management, risk management, potential addiction, or palliative care; and
- (v) best practices for recommending the form and dosage of medical cannabis products based on the qualifying condition underlying a medical cannabis recommendation.

(4) (a) Except as provided in Subsection (4)(b), a qualified medical provider may not recommend a medical cannabis treatment to more than 275 of the qualified medical provider's patients at the same time, as determined by the number of medical cannabis cards under the qualified medical provider's name in the state electronic verification system.

(b) A qualified medical provider may recommend a medical cannabis treatment to up

to 600 of the qualified medical provider's patients at any given time, as determined by the number of medical cannabis cards under the qualified medical provider's name in the state electronic verification system, if:

(i) the ~~[appropriate]~~ American ~~[medical board]~~ Board of Medical Specialties has certified the qualified medical provider in the specialty of anesthesiology, gastroenterology, neurology, oncology, pain, hospice and palliative medicine, physical medicine and rehabilitation, rheumatology, endocrinology, or psychiatry; or

(ii) a licensed business employs or contracts with the qualified medical provider for the specific purpose of providing hospice and palliative care.

(5) A recommending medical provider may recommend medical cannabis to an individual under this chapter only in the course of a provider-patient relationship after the recommending medical provider has completed and documented in the patient's medical record a thorough assessment of the patient's condition and medical history based on the appropriate standard of care for the patient's condition.

(6) (a) Except as provided in Subsection (6)(b), an individual may not advertise that the individual recommends a medical cannabis treatment.

(b) Notwithstanding Subsection (6)(a) and subject to Section [26-61a-116](#), a qualified medical provider or clinic or office that employs a qualified medical provider may advertise the following:

- (i) a green cross;
- (ii) the provider's or clinic's name and logo;
- (iii) a qualifying condition that the individual treats;
- (iv) that the individual is registered as a qualified medical provider and recommends medical cannabis; or
- (v) a scientific study regarding medical cannabis use.

(7) (a) A qualified medical provider registration card expires two years after the day on which the department issues the card.

(b) The department shall renew a qualified medical provider's registration card if the provider:

- (i) applies for renewal;
- (ii) is eligible for a qualified medical provider registration card under this section,

including maintaining an unrestricted license under the recommending qualifications;

(iii) certifies to the department in a renewal application that the information in Subsection (2)(a) is accurate or updates the information;

(iv) submits a report detailing the completion of the continuing education requirement described in Subsection (3); and

(v) pays the department a fee in an amount that:

(A) the department sets, in accordance with Section 63J-1-504; and

(B) does not exceed \$50 for a registration renewal.

(8) The department may revoke the registration of a qualified medical provider who fails to maintain compliance with the requirements of this section.

(9) A recommending medical provider may not receive any compensation or benefit for the qualified medical provider's medical cannabis treatment recommendation from:

(a) a cannabis production establishment or an owner, officer, director, board member, employee, or agent of a cannabis production establishment;

(b) a medical cannabis pharmacy or an owner, officer, director, board member, employee, or agent of a medical cannabis pharmacy; or

(c) a recommending medical provider or pharmacy medical provider.

(10) (a) On or before November 1, 2021, a qualified medical provider shall report to the department, in a manner designated by the department:

(i) if applicable, that the qualified medical provider or the entity that employs the qualified medical provider represents online or on printed material that the qualified medical provider is a qualified medical provider or offers medical cannabis recommendations to patients; and

(ii) the fee amount that the qualified medical provider or the entity that employs the qualified medical provider charges a patient for a medical cannabis recommendation, either as an actual cash rate or, if the provider or entity bills insurance, an average cash rate.

(b) The department shall:

(i) ensure that the following information related to qualified medical providers and entities described in Subsection (10)(a)(i) is available on the department's website or on the health care price transparency tool under Subsection (10)(b)(ii):

(A) the name of the qualified medical provider and, if applicable, the name of the

entity that employs the qualified medical provider;

(B) the address of the qualified medical provider's office or, if applicable, the entity that employs the qualified medical provider; and

(C) the fee amount described in Subsection (10)(a)(ii); and

(ii) share data collected under this Subsection (10) with the state auditor for use in the health care price transparency tool described in Section [67-3-11](#).

Section 7. Section **26-61a-116** is amended to read:

26-61a-116. Advertising.

(1) Except as provided in this chapter, a person may not advertise regarding the recommendation, sale, dispensing, or transportation of medical cannabis[-], including:

(a) a promotional discount or incentive;

(b) a particular medical cannabis product, medical cannabis device, medical cannabis brand, or medicinal dosage form; or

(c) an assurance of a medical outcome related to a medical cannabis treatment.

~~[(2) Notwithstanding any authorization to advertise regarding medical cannabis under this chapter, the person advertising may not advertise:]~~

~~[(a) using promotional discounts or incentives;]~~

~~[(b) a particular medical cannabis product, medical cannabis device, or medicinal dosage form; or]~~

~~[(c) an assurance regarding an outcome related to medical cannabis treatment.]~~

~~[(3)]~~ (2) Notwithstanding Subsection (1):

(a) a nonprofit organization that offers financial assistance for medical cannabis treatment to low-income patients may advertise the organization's assistance if the advertisement does not relate to a specific medical cannabis pharmacy or a specific medical cannabis product; and

(b) a medical cannabis pharmacy may provide information regarding subsidies for the cost of medical cannabis treatment to patients who affirmatively accept receipt of the subsidy information.

~~[(4)]~~ (3) To ensure that the name and logo of a licensee under this chapter have a medical rather than a recreational disposition, the name and logo of the licensee:

(a) may include terms and images associated with:

(i) a medical disposition, including "medical," "medicinal," "medicine," "pharmacy," "apothecary," "wellness," "therapeutic," "health," "care," "cannabis," "clinic," "compassionate," "relief," "treatment," and "patient;" or

(ii) the plant form of cannabis, including "leaf," "flower," and "bloom";

(b) may not include:

(i) any term, statement, design representation, picture, or illustration that is associated with a recreational disposition or that appeals to children;

(ii) an emphasis on a psychoactive ingredient;

(iii) a specific cannabis strain; or

(iv) terms related to recreational marijuana, including "weed," "pot," "reefer," "grass," "hash," "ganga," "Mary Jane," "high," "buzz," "haze," "stoned," "joint," "bud," "smoke," "euphoria," "dank," "doobie," "kush," "frost," "cookies," "rec," "bake," "blunt," "combust," "bong," "budtender," "dab," "blaze," "toke," or "420."

[5] (4) The department shall define standards for advertising authorized under this chapter, including names and logos in accordance with Subsection (4), to ensure a medical rather than recreational disposition.

Section 8. Section **26-61a-117** is enacted to read:

26-61a-117. Government issued photo identification.

A government issued photo identification is valid for purposes of this chapter if the identification:

(1) is unexpired;

(2) expired within the previous six months; or

(3) is expired and belongs to an individual who:

(a) as reported by the individual's recommending medical provider is in hospice or has a terminal illness; or

(b) is a patient or resident of:

(i) an assisted living facility, as defined in Section 26-21-2;

(ii) a nursing care facility, as defined in Section 26-21-2; or

(iii) a general acute hospital, as defined in Section 26-21-2.

Section 9. Section **26-61a-201** is amended to read:

26-61a-201. Medical cannabis patient card -- Medical cannabis guardian card --

Conditional medical cannabis card -- Application -- Fees -- Studies.

(1) (a) ~~[The department shall;]~~ Subject to Section [26-61a-206](#), within 15 days after the day on which an individual who satisfies the eligibility criteria in this section or Section [26-61a-202](#) submits an application in accordance with this section or Section [26-61a-202](#), the department shall:

- (i) issue a medical cannabis patient card to an individual described in Subsection (2)(a);
- (ii) issue a medical cannabis guardian card to an individual described in Subsection (2)(b);
- (iii) issue a provisional patient card to a minor described in Subsection (2)(c); and
- (iv) issue a medical cannabis caregiver card to an individual described in Subsection [26-61a-202](#)(4).

(b) (i) ~~[Beginning on the earlier of September 1, 2021, or the date on which the electronic verification system is functionally capable of facilitating a conditional medical cannabis card under this Subsection (1)(b), upon]~~ Upon the entry of a recommending medical provider's medical cannabis recommendation for a patient in the state electronic verification system, either by the provider or the provider's employee or by a medical cannabis pharmacy medical provider or medical cannabis pharmacy in accordance with Subsection [26-61a-501](#)(10)(a), the department shall issue to the patient an electronic conditional medical cannabis card, in accordance with this Subsection (1)(b).

(ii) A conditional medical cannabis card is valid for the lesser of:

- (A) 60 days; or
- (B) the day on which the department completes the department's review and issues a medical cannabis card under Subsection (1)(a), denies the patient's medical cannabis card application, or revokes the conditional medical cannabis card under Subsection (8).

(iii) The department may issue a conditional medical cannabis card to an individual applying for a medical cannabis patient card for which approval of the Compassionate Use Board is not required.

(iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and obligations under law applicable to a holder of the medical cannabis card for which the individual applies and for which the department issues the conditional medical cannabis card.

989 (2) (a) An individual is eligible for a medical cannabis patient card if:

990 (i) (A) the individual is at least 21 years old; or

991 (B) the individual is 18, 19, or 20 years old, the individual petitions the Compassionate

992 Use Board under Section 26-61a-105, and the Compassionate Use Board recommends

993 department approval of the petition;

994 (ii) the individual is a Utah resident;

995 (iii) the individual's recommending medical provider recommends treatment with

996 medical cannabis in accordance with Subsection (4);

997 (iv) the individual signs an acknowledgment stating that the individual received the

998 information described in Subsection (9); and

999 (v) the individual pays to the department a fee in an amount that, subject to Subsection

1000 26-61a-109(5), the department sets in accordance with Section 63J-1-504.

1001 (b) (i) An individual is eligible for a medical cannabis guardian card if the individual:

1002 (A) is at least 18 years old;

1003 (B) is a Utah resident;

1004 (C) is the parent or legal guardian of a minor for whom the minor's qualified medical

1005 provider recommends a medical cannabis treatment, the individual petitions the Compassionate

1006 Use Board under Section 26-61a-105, and the Compassionate Use Board recommends

1007 department approval of the petition;

1008 (D) the individual signs an acknowledgment stating that the individual received the

1009 information described in Subsection (9); and

1010 (E) pays to the department a fee in an amount that, subject to Subsection

1011 26-61a-109(5), the department sets in accordance with Section 63J-1-504, plus the cost of the

1012 criminal background check described in Section 26-61a-203[~~;~~and].

1013 [~~(F) the individual has not been convicted of a misdemeanor or felony drug distribution~~

1014 ~~offense under either state or federal law, unless the individual completed any imposed sentence~~

1015 ~~six months or more before the day on which the individual applies for a medical cannabis~~

1016 ~~guardian card.]~~

1017 (ii) The department shall notify the Department of Public Safety of each individual that

1018 the department registers for a medical cannabis guardian card.

1019 (c) (i) A minor is eligible for a provisional patient card if:

1020 (A) the minor has a qualifying condition;

1021 (B) the minor's qualified medical provider recommends a medical cannabis treatment
1022 to address the minor's qualifying condition;

1023 (C) one of the minor's parents or legal guardians petitions the Compassionate Use
1024 Board under Section 26-61a-105, and the Compassionate Use Board recommends department
1025 approval of the petition; and

1026 (D) the minor's parent or legal guardian is eligible for a medical cannabis guardian card
1027 under Subsection (2)(b) or designates a caregiver under Subsection (2)(d) who is eligible for a
1028 medical cannabis caregiver card under Section 26-61a-202.

1029 (ii) The department shall automatically issue a provisional patient card to the minor
1030 described in Subsection (2)(c)(i) at the same time the department issues a medical cannabis
1031 guardian card to the minor's parent or legal guardian.

1032 (d) ~~[Beginning on the earlier of September 1, 2021, or the date on which the electronic~~
1033 ~~verification system is functionally capable of servicing the designation, if]~~ If the parent or legal
1034 guardian of a minor described in Subsections (2)(c)(i)(A) through (C) does not qualify for a
1035 medical cannabis guardian card under Subsection (2)(b), the parent or legal guardian may
1036 designate up to two caregivers in accordance with Subsection 26-61a-202(1)(c) to ensure that
1037 the minor has adequate and safe access to the recommended medical cannabis treatment.

1038 (3) (a) An individual who is eligible for a medical cannabis card described in
1039 Subsection (2)(a) or (b) shall submit an application for a medical cannabis card to the
1040 department:

1041 (i) through an electronic application connected to the state electronic verification
1042 system;

1043 (ii) with the recommending medical provider; and

1044 (iii) with information including:

1045 (A) the applicant's name, gender, age, and address;

1046 (B) the number of the applicant's ~~[valid form of]~~ government issued photo
1047 identification;

1048 (C) for a medical cannabis guardian card, the name, gender, and age of the minor
1049 receiving a medical cannabis treatment under the cardholder's medical cannabis guardian card;
1050 and

(D) for a provisional patient card, the name of the minor's parent or legal guardian who holds the associated medical cannabis guardian card.

(b) The department shall ensure that a medical cannabis card the department issues under this section contains the information described in Subsection (3)(a)(iii).

(c) (i) If a recommending medical provider determines that, because of age, illness, or disability, a medical cannabis patient cardholder requires assistance in administering the medical cannabis treatment that the recommending medical provider recommends, the recommending medical provider may indicate the cardholder's need in the state electronic verification system, either directly or, for a limited medical provider, through the order described in Subsections 26-61a-106(1)(c) and (d).

(ii) If a recommending medical provider makes the indication described in Subsection (3)(c)(i):

(A) the department shall add a label to the relevant medical cannabis patient card indicating the cardholder's need for assistance;

(B) any adult who is 18 years old or older and who is physically present with the cardholder at the time the cardholder needs to use the recommended medical cannabis treatment may handle the medical cannabis treatment and any associated medical cannabis device as needed to assist the cardholder in administering the recommended medical cannabis treatment; and

(C) an individual of any age who is physically present with the cardholder in the event of an emergency medical condition, as that term is defined in Section 31A-1-301, may handle the medical cannabis treatment and any associated medical cannabis device as needed to assist the cardholder in administering the recommended medical cannabis treatment.

(iii) A non-cardholding individual acting under Subsection (3)(c)(ii)(B) or (C) may not:

(A) ingest or inhale medical cannabis;

(B) possess, transport, or handle medical cannabis or a medical cannabis device outside of the immediate area where the cardholder is present or with an intent other than to provide assistance to the cardholder; or

(C) possess, transport, or handle medical cannabis or a medical cannabis device when the cardholder is not in the process of being dosed with medical cannabis.

(4) To recommend a medical cannabis treatment to a patient or to renew a

recommendation, a recommending medical provider shall:

(a) visit with the patient face-to-face for an initial recommendation unless the patient:

(i) prefers a virtual visit; and

(ii) (A) is on hospice or has a terminal illness according to the patient's medical provider; or

(B) is a resident of an assisted living facility, as defined in Section 26-21-2, or a nursing care facility, as defined in Section 26-21-2;

(b) before recommending or renewing a recommendation for medical cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form:

(i) verify the patient's and, for a minor patient, the minor patient's parent or legal guardian's [valid form of identification] government issued photo identification described in Subsection (3)(a);

(ii) review any record related to the patient and, for a minor patient, the patient's parent or legal guardian in:

(A) for a qualified medical provider, the state electronic verification system; and

(B) the controlled substance database created in Section 58-37f-201; and

(iii) consider the recommendation in light of the patient's qualifying condition, history of substance use or opioid use disorder, and history of medical cannabis and controlled substance use during [an initial face-to-face] a visit with the patient; and

[~~(b)~~] (c) state in the recommending medical provider's recommendation that the patient:

(i) suffers from a qualifying condition, including the type of qualifying condition; and

(ii) may benefit from treatment with cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form.

(5) (a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the department issues under this section is valid for the lesser of:

(i) an amount of time that the recommending medical provider determines; or

(ii) one year from the day the card is issued.

[~~(ii) (A) six months for the first issuance, and, except as provided in Subsection (5)(a)(ii)(B), for a renewal; or~~]

[~~(B) for a renewal, one year if, after at least one year following the issuance of the~~]

1113 ~~original medical cannabis card, the recommending medical provider determines that the patient~~
1114 ~~has been stabilized on the medical cannabis treatment and a one-year renewal period is~~
1115 ~~justified.]~~

1116 (b) (i) A medical cannabis card that the department issues in relation to a terminal
1117 illness described in Section 26-61a-104 expires after one year.

1118 (ii) The recommending medical provider may revoke a recommendation that the
1119 provider made in relation to a terminal illness described in Section 26-61a-104 if the medical
1120 cannabis cardholder no longer has the terminal illness.

1121 (c) A medical cannabis card that the department issues in relation to acute pain as
1122 described in Section 26-61a-104 expires 30 days after the day on which the department first
1123 issues a conditional or full medical cannabis card.

1124 (6) (a) A medical cannabis patient card or a medical cannabis guardian card is
1125 renewable if:

1126 (i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a) or
1127 (b); or

1128 (ii) the cardholder received the medical cannabis card through the recommendation of
1129 the Compassionate Use Board under Section 26-61a-105.

1130 (b) The recommending medical provider who made the underlying recommendation
1131 for the card of a cardholder described in Subsection (6)(a) may renew the cardholder's card
1132 through phone or video conference with the cardholder, at the recommending medical
1133 provider's discretion.

1134 (c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b)
1135 shall pay to the department a renewal fee in an amount that:

1136 (i) subject to Subsection 26-61a-109(5), the department sets in accordance with Section
1137 63J-1-504; and

1138 (ii) may not exceed the cost of the relatively lower administrative burden of renewal in
1139 comparison to the original application process.

1140 (d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional
1141 patient card renews automatically at the time the minor's parent or legal guardian renews the
1142 parent or legal guardian's associated medical cannabis guardian card.

1143 (7) (a) A cardholder under this section shall carry the cardholder's valid medical

cannabis card with the patient's name.

(b) (i) A medical cannabis patient cardholder or a provisional patient cardholder may purchase, in accordance with this chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device.

(ii) A cardholder under this section may possess or transport, in accordance with this chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device.

(iii) To address the qualifying condition underlying the medical cannabis treatment recommendation:

(A) a medical cannabis patient cardholder or a provisional patient cardholder may use cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form, or a medical cannabis device; and

(B) a medical cannabis guardian cardholder may assist the associated provisional patient cardholder with the use of cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form, or a medical cannabis device.

(8) (a) The department may revoke a medical cannabis card that the department issues under this section if:

(i) the recommending medical provider withdraws the medical provider's recommendation for medical cannabis; or

(ii) the cardholder:

~~[(a)]~~ (A) violates this chapter; or

~~[(b)]~~ (B) is convicted under state or federal law of, after March 17, 2021, a drug distribution offense.

(b) The department may not refuse to issue a medical cannabis card to a patient solely based on a prior revocation under Subsection (8)(a)(i).

(9) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, a process to provide information regarding the following to an individual receiving a medical cannabis card:

(a) risks associated with medical cannabis treatment;

(b) the fact that a condition's listing as a qualifying condition does not suggest that

medical cannabis treatment is an effective treatment or cure for that condition, as described in Subsection 26-61a-104(1); and

(c) other relevant warnings and safety information that the department determines.

(10) The department may establish procedures by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to implement the application and issuance provisions of this section.

(11) (a) On or before September 1, 2021, the department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, a process to allow an individual from another state to register with the department in order to purchase medical cannabis or a medical cannabis device from a medical cannabis pharmacy while the individual is visiting the state.

(b) The department may only provide the registration process described in Subsection (11)(a):

(i) to a nonresident patient; and

(ii) for no more than two visitation periods per calendar year of up to 21 calendar days per visitation period.

(12) (a) A person may submit to the department a request to conduct a research study using medical cannabis cardholder data that the state electronic verification system contains.

(b) The department shall review a request described in Subsection (12)(a) to determine whether an institutional review board, as that term is defined in Section 26-61-102, could approve the research study.

(c) At the time an individual applies for a medical cannabis card, the department shall notify the individual:

(i) of how the individual's information will be used as a cardholder;

(ii) that by applying for a medical cannabis card, unless the individual withdraws consent under Subsection (12)(d), the individual consents to the use of the individual's information for external research; and

(iii) that the individual may withdraw consent for the use of the individual's information for external research at any time, including at the time of application.

(d) An applicant may, through the medical cannabis card application, and a medical cannabis cardholder may, through the state central patient portal, withdraw the applicant's or

1206 cardholder's consent to participate in external research at any time.

1207 (e) The department may release, for the purposes of a study described in this
1208 Subsection (12), information about a cardholder under this section who consents to participate
1209 under Subsection (12)(c).

1210 (f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of
1211 consent:

1212 (i) applies to external research that is initiated after the withdrawal of consent; and

1213 (ii) does not apply to research that was initiated before the withdrawal of consent.

1214 (g) The department may establish standards for a medical research study's validity, by
1215 rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.

1216 (13) The department shall record the issuance or revocation of a medical cannabis card
1217 under this section in the controlled substance database.

1218 Section 10. Section **26-61a-202** is amended to read:

1219 **26-61a-202. Medical cannabis caregiver card -- Registration -- Renewal --**
1220 **Revocation.**

1221 (1) (a) A cardholder described in Section **26-61a-201** may designate, through the state
1222 central patient portal, up to two individuals, or an individual and a facility in accordance with
1223 Subsection (1)(b), to serve as a designated caregiver for the cardholder.

1224 (b) (i) Beginning on the earlier of September 1, 2021, or the date on which the
1225 electronic verification system is functionally capable of servicing the designation, a cardholder
1226 described in Section **26-61a-201** may designate one of the following types of facilities as one of
1227 the caregivers described in Subsection (1)(a):

1228 (A) for a patient or resident, an assisted living facility, as that term is defined in Section
1229 **26-21-2**;

1230 (B) for a patient or resident, a nursing care facility, as that term is defined in Section
1231 **26-21-2**; or

1232 (C) for a patient, a general acute hospital, as that term is defined in Section **26-21-2**.

1233 (ii) A facility may:

1234 (A) assign one or more employees to assist patients with medical cannabis treatment
1235 under the caregiver designation described in this Subsection (1)(b); and

1236 (B) receive a medical cannabis shipment from a medical cannabis pharmacy or a

1237 medical cannabis courier on behalf of the medical cannabis cardholder within the facility who
1238 designated the facility as a caregiver.

1239 (iii) The department shall make rules to regulate the practice of facilities and facility
1240 employees serving as designated caregivers under this Subsection (1)(b).

1241 (c) A parent or legal guardian described in Subsection 26-61a-201(2)(d), in
1242 consultation with the minor and the minor's qualified medical provider, may designate, through
1243 the state central patient portal, up to two individuals to serve as a designated caregiver for the
1244 minor, if the department determines that the parent or legal guardian is not eligible for a
1245 medical cannabis guardian card under Section 26-61a-201.

1246 (d) (i) Beginning on the earlier of September 1, 2022, or the date on which the
1247 electronic verification system is functionally capable of facilitating a conditional medical
1248 cannabis caregiver card under this Subsection (1)(d), upon the entry of a caregiver designation
1249 under Subsection (1) by a patient with a terminal illness described in Section 26-61a-104, the
1250 department shall issue to the designated caregiver an electronic conditional medical cannabis
1251 caregiver card, in accordance with this Subsection (1)(d).

1252 (ii) A conditional medical cannabis caregiver card is valid for the lesser of:

1253 (A) 60 days; or

1254 (B) the day on which the department completes the department's review and issues a
1255 medical cannabis caregiver card under Subsection (1)(a), denies the patient's medical cannabis
1256 caregiver card application, or revokes the conditional medical cannabis caregiver card under
1257 Subsection (8).

1258 (iii) The department may issue a conditional medical cannabis card to an individual
1259 applying for a medical cannabis patient card for which approval of the Compassionate Use
1260 Board is not required.

1261 (iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and
1262 obligations under law applicable to a holder of the medical cannabis card for which the
1263 individual applies and for which the department issues the conditional medical cannabis card.

1264 (2) An individual that the department registers as a designated caregiver under this
1265 section and a facility described in Subsection (1)(b):

1266 (a) for an individual designated caregiver, may carry a valid medical cannabis caregiver
1267 card;

(b) in accordance with this chapter, may purchase, possess, transport, or assist the patient in the use of cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device on behalf of the designating medical cannabis cardholder;

(c) may not charge a fee to an individual to act as the individual's designated caregiver or for a service that the designated caregiver provides in relation to the role as a designated caregiver; and

(d) may accept reimbursement from the designating medical cannabis cardholder for direct costs the designated caregiver incurs for assisting with the designating cardholder's medicinal use of cannabis.

(3) (a) The department shall:

(i) within 15 days after the day on which an individual submits an application in compliance with this section, issue a medical cannabis card to the applicant if the applicant:

(A) is designated as a caregiver under Subsection (1);

(B) is eligible for a medical cannabis caregiver card under Subsection (4); and

(C) complies with this section; and

(ii) notify the Department of Public Safety of each individual that the department registers as a designated caregiver.

(b) The department shall ensure that a medical cannabis caregiver card contains the information described in Subsections (5)(b) and (3)(c)(i).

(c) If a cardholder described in Section 26-61a-201 designates an individual as a caregiver who already holds a medical cannabis caregiver card, the individual with the medical cannabis caregiver card:

(i) shall report to the department the information required of applicants under Subsection (5)(b) regarding the new designation;

(ii) if the individual makes the report described in Subsection (3)(c)(i), is not required to file an application for another medical cannabis caregiver card;

(iii) may receive an additional medical cannabis caregiver card in relation to each additional medical cannabis patient who designates the caregiver; and

(iv) is not subject to an additional background check.

(4) An individual is eligible for a medical cannabis caregiver card if the individual:

- 1299 (a) is at least 21 years old;
- 1300 (b) is a Utah resident;
- 1301 (c) pays to the department a fee in an amount that, subject to Subsection
- 1302 26-61a-109(5), the department sets in accordance with Section 63J-1-504, plus the cost of the
- 1303 criminal background check described in Section 26-61a-203; and
- 1304 (d) signs an acknowledgment stating that the applicant received the information
- 1305 described in Subsection 26-61a-201(9)[; and].
- 1306 ~~[(e) has not been convicted of a misdemeanor or felony drug distribution offense that is~~
- 1307 ~~a felony under either state or federal law, unless the individual completes any imposed sentence~~
- 1308 ~~two or more years before the day on which the individual submits the application.]~~
- 1309 (5) An eligible applicant for a medical cannabis caregiver card shall:
- 1310 (a) submit an application for a medical cannabis caregiver card to the department
- 1311 through an electronic application connected to the state electronic verification system; and
- 1312 (b) submit the following information in the application described in Subsection (5)(a):
- 1313 (i) the applicant's name, gender, age, and address;
- 1314 (ii) the name, gender, age, and address of the cardholder described in Section
- 1315 26-61a-201 who designated the applicant;
- 1316 (iii) if a medical cannabis guardian cardholder designated the caregiver, the name,
- 1317 gender, and age of the minor receiving a medical cannabis treatment in relation to the medical
- 1318 cannabis guardian cardholder; and
- 1319 (iv) any additional information that the department requests to assist in matching the
- 1320 application with the designating medical cannabis patient.
- 1321 (6) Except as provided in Subsection (6)(b), a medical cannabis caregiver card that the
- 1322 department issues under this section is valid for the lesser of:
- 1323 (a) an amount of time that the cardholder described in Section 26-61a-201 who
- 1324 designated the caregiver determines; or
- 1325 (b) the amount of time remaining before the card of the cardholder described in Section
- 1326 26-61a-201 expires.
- 1327 (7) (a) If a designated caregiver meets the requirements of Subsection (4), the
- 1328 designated caregiver's medical cannabis caregiver card renews automatically at the time the
- 1329 cardholder described in Section 26-61a-201 who designated the caregiver:

1330 (i) renews the cardholder's card; and
1331 (ii) renews the caregiver's designation, in accordance with Subsection (7)(b).
1332 (b) The department shall provide a method in the card renewal process to allow a
1333 cardholder described in Section 26-61a-201 who has designated a caregiver to:
1334 (i) signify that the cardholder renews the caregiver's designation;
1335 (ii) remove a caregiver's designation; or
1336 (iii) designate a new caregiver.
1337 ~~[(8) The department may revoke a medical cannabis caregiver card if the designated~~
1338 ~~caregiver:]~~
1339 ~~[(a) violates this chapter; or]~~
1340 ~~[(b) is convicted under state or federal law of:]~~
1341 ~~[(i) a felony drug distribution offense; or]~~
1342 ~~[(ii) after December 3, 2018, a misdemeanor drug distribution offense.]~~
1343 ~~[(9)]~~ (8) The department shall record the issuance or revocation of a medical cannabis
1344 card under this section in the controlled substance database.
1345 Section 11. Section 26-61a-206 is enacted to read:
1346 **26-61a-206. Denial or revocation of guardian and caregiver card.**
1347 The department may deny or revoke a medical cannabis guardian card or a medical
1348 cannabis caregiver card if the applicant or cardholder:
1349 (1) violates the requirements of this chapter; or
1350 (2) unless the individual completes any imposed sentence two or more years before the
1351 day on which the individual submits the application, has been convicted of any of the following
1352 under state or federal law:
1353 (a) a drug distribution offense that is a felony within the preceding 10 years; or
1354 (b) after December 3, 2018, a drug distribution offense that is a misdemeanor.
1355 Section 12. Section 26-61a-301 is amended to read:
1356 **26-61a-301. Medical cannabis pharmacy -- License -- Eligibility.**
1357 (1) A person may not operate as a medical cannabis pharmacy without a license that
1358 the department issues under this part.
1359 (2) (a) (i) Subject to Subsections (4) and (5) and to Section 26-61a-305, the department
1360 shall issue a license to operate a medical cannabis pharmacy in accordance with Title 63G,

Chapter 6a, Utah Procurement Code.

(ii) The department may not issue a license to operate a medical cannabis pharmacy to an applicant who is not eligible for a license under this section.

(b) An applicant is eligible for a license under this section if the applicant submits to the department:

(i) subject to Subsection (2)(c), a proposed name and address where the applicant will operate the medical cannabis pharmacy;

(ii) the name and address of an individual who:

(A) for a publicly traded company, has a financial or voting interest of [2] 10% or greater in the proposed medical cannabis pharmacy;

(B) for a privately held company, a financial or voting interest in the proposed medical cannabis pharmacy; or

(C) has the power to direct or cause the management or control of a proposed medical cannabis pharmacy;

(iii) ~~[a statement that the applicant will obtain and maintain a performance bond that a surety authorized to transact surety business in the state issues in an amount of at least \$100,000]~~ for each application that the applicant submits to the department, a statement from the applicant that the applicant will obtain and maintain:

(A) a performance bond in the amount of \$100,000 issued by a surety authorized to transact surety business in the state; or

(B) a liquid cash account in the amount of \$100,000 with a financial institution;

(iv) an operating plan that:

(A) complies with Section 26-61a-304;

(B) includes operating procedures to comply with the operating requirements for a medical cannabis pharmacy described in this chapter and with a relevant municipal or county law that is consistent with Section 26-61a-507; and

(C) the department approves;

(v) an application fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504; and

(vi) a description of any investigation or adverse action taken by any licensing jurisdiction, government agency, law enforcement agency, or court in any state for any

violation or detrimental conduct in relation to any of the applicant's cannabis-related operations or businesses.

(c) (i) A person may not locate a medical cannabis pharmacy:

(A) within 200 feet of a community location; or

(B) in or within 600 feet of a district that the relevant municipality or county has zoned as primarily residential.

(ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured from the nearest entrance to the medical cannabis pharmacy establishment by following the shortest route of ordinary pedestrian travel to the property boundary of the community location or residential area.

(iii) The department may grant a waiver to reduce the proximity requirements in Subsection (2)(c)(i) by up to 20% if the department determines that it is not reasonably feasible for the applicant to site the proposed medical cannabis pharmacy without the waiver.

(iv) An applicant for a license under this section shall provide evidence of compliance with the proximity requirements described in Subsection (2)(c)(i).

(d) The department may not issue a license to an eligible applicant that the department has selected to receive a license until the selected eligible applicant ~~[obtains the performance bond described in]~~ complies with the bond or liquid cash requirement described in Subsection (2)(b)(iii).

(e) If the department receives more than one application for a medical cannabis pharmacy within the same city or town, the department shall consult with the local land use authority before approving any of the applications pertaining to that city or town.

(3) If the department selects an applicant for a medical cannabis pharmacy license under this section, the department shall:

(a) charge the applicant an initial license fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504;

(b) notify the Department of Public Safety of the license approval and the names of each individual described in Subsection (2)(b)(ii); and

(c) charge the licensee a fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504, for any change in location, ownership, or company structure.

1423 (4) The department may not issue a license to operate a medical cannabis pharmacy to
1424 an applicant if an individual described in Subsection (2)(b)(ii):

1425 (a) has been convicted under state or federal law of:

1426 (i) a felony; or

1427 (ii) after December 3, 2018, a misdemeanor for drug distribution;

1428 (b) is younger than 21 years old; or

1429 (c) after September 23, 2019, until January 1, 2023, is actively serving as a legislator.

1430 (5) (a) If an applicant for a medical cannabis pharmacy license under this section holds
1431 a license under Title 4, Chapter 41, Hemp and Cannabinoid Act, the department may not give
1432 preference to the applicant based on the applicant's status as a holder of the license.

1433 (b) If an applicant for a medical cannabis pharmacy license under this section holds a
1434 license to operate a cannabis cultivation facility under Title 4, Chapter 41a, Cannabis
1435 Production Establishments, the department:

1436 (i) shall consult with the Department of Agriculture and Food regarding the applicant;
1437 and

1438 (ii) may give consideration to the applicant based on the applicant's status as a holder
1439 of a license to operate a cannabis cultivation facility if:

1440 (A) the applicant demonstrates that a decrease in costs to patients is more likely to
1441 result from the applicant's vertical integration than from a more competitive marketplace; and

1442 (B) the department finds multiple other factors, in addition to the existing license, that
1443 support granting the new license.

1444 (6) (a) The department may revoke a license under this part:

1445 (i) if the medical cannabis pharmacy does not begin operations within one year after
1446 the day on which the department issues an announcement of the department's intent to award a
1447 license to the medical cannabis pharmacy;

1448 (ii) after the third the same violation of this chapter in any of the licensee's licensed
1449 cannabis production establishments or medical cannabis pharmacies;

1450 (iii) if an individual described in Subsection (2)(b)(ii) is convicted, while the license is
1451 active, under state or federal law of:

1452 (A) a felony; or

1453 (B) after December 3, 2018, a misdemeanor for drug distribution;

(iv) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at the time of application, or fails to supplement the information described in Subsection (2)(b)(vi) with any investigation or adverse action that occurs after the submission of the application within 14 calendar days after the licensee receives notice of the investigation or adverse action;

(v) if the medical cannabis pharmacy demonstrates a willful or reckless disregard for the requirements of this chapter or the rules the department makes in accordance with this chapter; or

(vi) if, after a change of ownership described in Subsection (11)(c), the department determines that the medical cannabis pharmacy no longer meets the minimum standards for licensure and operation of the medical cannabis pharmacy described in this chapter.

(b) The department shall rescind a notice of an intent to issue a license under this part to an applicant or revoke a license issued under this part if the associated medical cannabis pharmacy does not begin operation on or before June 1, 2021.

(7) (a) A person who receives a medical cannabis pharmacy license under this chapter, if the municipality or county where the licensed medical cannabis pharmacy will be located requires a local land use permit, shall submit to the department a copy of the licensee's approved application for the land use permit within 120 days after the day on which the department issues the license.

(b) If a licensee fails to submit to the department a copy the licensee's approved land use permit application in accordance with Subsection (7)(a), the department may revoke the licensee's license.

(8) The department shall deposit the proceeds of a fee imposed by this section into the Qualified Patient Enterprise Fund.

(9) The department shall begin accepting applications under this part on or before March 1, 2020.

(10) (a) The department's authority to issue a license under this section is plenary and is not subject to review.

(b) Notwithstanding Subsection (2), the decision of the department to award a license to an applicant is not subject to:

(i) Title 63G, Chapter 6a, Part 16, Protests; or

- 1485 (ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.
- 1486 (11) (a) A medical cannabis pharmacy license is not transferrable or assignable.
- 1487 (b) A medical cannabis pharmacy shall report in writing to the department no later than
- 1488 10 business days before the date of any change of ownership of the medical cannabis
- 1489 pharmacy.
- 1490 (c) If the ownership of a medical cannabis pharmacy changes by 50% or more:
- 1491 (i) concurrent with the report described in Subsection (11)(b), the medical cannabis
- 1492 pharmacy shall submit a new application described in Subsection (2)(b), subject to Subsection
- 1493 (2)(c);
- 1494 (ii) within 30 days of the submission of the application, the department shall:
- 1495 (A) conduct an application review; and
- 1496 (B) award a license to the medical cannabis pharmacy for the remainder of the term of
- 1497 the medical cannabis pharmacy's license before the ownership change if the medical cannabis
- 1498 pharmacy meets the minimum standards for licensure and operation of the medical cannabis
- 1499 pharmacy described in this chapter; and
- 1500 (iii) if the department approves the license application, notwithstanding Subsection (3),
- 1501 the medical cannabis pharmacy shall pay a license fee that the department sets in accordance
- 1502 with Section 63J-1-504 in an amount that covers the board's cost of conducting the application
- 1503 review.
- 1504 Section 13. Section **26-61a-302** is amended to read:
- 1505 **26-61a-302. Medical cannabis pharmacy owners and directors -- Criminal**
- 1506 **background checks.**
- 1507 (1) Each applicant to whom the department issues a notice of intent to award a license
- 1508 to operate as a medical cannabis pharmacy shall submit, before the department may award the
- 1509 license, from each individual who has a financial or voting interest of [2] 10% or greater in the
- 1510 applicant or who has the power to direct or cause the management or control of the applicant:
- 1511 (a) a fingerprint card in a form acceptable to the Department of Public Safety;
- 1512 (b) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the
- 1513 registration of the individual's fingerprints in the Federal Bureau of Investigation Next
- 1514 Generation Identification System's Rap Back Service; and
- 1515 (c) consent to a fingerprint background check by:

(i) the Bureau of Criminal Identification; and

(ii) the Federal Bureau of Investigation.

(2) The Bureau of Criminal Identification shall:

(a) check the fingerprints the applicant submits under Subsection (1) against the applicable state, regional, and national criminal records databases, including the Federal Bureau of Investigation Next Generation Identification System;

(b) report the results of the background check to the department;

(c) maintain a separate file of fingerprints that applicants submit under Subsection (1) for search by future submissions to the local and regional criminal records databases, including latent prints;

(d) request that the fingerprints be retained in the Federal Bureau of Investigation Next Generation Identification System's Rap Back Service for search by future submissions to national criminal records databases, including the Next Generation Identification System and latent prints; and

(e) establish a privacy risk mitigation strategy to ensure that the department only receives notifications for an individual with whom the department maintains an authorizing relationship.

(3) The department shall:

(a) assess an individual who submits fingerprints under Subsection (1) a fee in an amount that the department sets in accordance with Section 63J-1-504 for the services that the Bureau of Criminal Identification or another authorized agency provides under this section; and

(b) remit the fee described in Subsection (3)(a) to the Bureau of Criminal Identification.

Section 14. Section **26-61a-403** is amended to read:

26-61a-403. Pharmacy medical providers -- Registration -- Continuing education.

(1) (a) A medical cannabis pharmacy:

(i) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy Practice Act, as a pharmacy medical provider;

(ii) may employ a physician who has the authority to write a prescription and is licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act, as a pharmacy medical provider;

(iii) shall ensure that a pharmacy medical provider described in Subsection (1)(a)(i) works onsite during all business hours; and

(iv) shall designate one pharmacy medical provider described in Subsection (1)(a)(i) as the pharmacist-in-charge to oversee the operation of and generally supervise the medical cannabis pharmacy.

(b) An individual may not serve as a pharmacy medical provider unless the department registers the individual as a pharmacy medical provider in accordance with Subsection (2).

(2) (a) The department shall, within 15 days after the day on which the department receives an application from a medical cannabis pharmacy on behalf of a prospective pharmacy medical provider, register and issue a pharmacy medical provider registration card to the prospective pharmacy medical provider if the medical cannabis pharmacy:

(i) provides to the department:

(A) the prospective pharmacy medical provider's name and address;

(B) the name and location of the licensed medical cannabis pharmacy where the prospective pharmacy medical provider seeks to act as a pharmacy medical provider;

(C) a report detailing the completion of the continuing education requirement described in Subsection (3); and

(D) evidence that the prospective pharmacy medical provider is a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy Practice Act, or a physician who has the authority to write a prescription and is licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and

(ii) pays a fee to the department in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504.

(b) The department may not register a recommending medical provider [~~or a state central patient portal medical provider~~] as a pharmacy medical provider.

(3) (a) A pharmacy medical provider shall complete the continuing education described in this Subsection (3) in the following amounts:

(i) as a condition precedent to registration, four hours; and

(ii) as a condition precedent to renewal of the registration, four hours every two years.

(b) In accordance with Subsection (3)(a), the pharmacy medical provider shall:

(i) complete continuing education:

1578 (A) regarding the topics described in Subsection (3)(d); and
1579 (B) offered by the department under Subsection (3)(c) or an accredited or approved
1580 continuing education provider that the department recognizes as offering continuing education
1581 appropriate for the medical cannabis pharmacy practice; and
1582 (ii) make a continuing education report to the department in accordance with a process
1583 that the department establishes by rule, in accordance with Title 63G, Chapter 3, Utah
1584 Administrative Rulemaking Act, and in collaboration with the Division of Professional
1585 Licensing and:
1586 (A) for a pharmacy medical provider who is licensed under Title 58, Chapter 17b,
1587 Pharmacy Practice Act, the Board of Pharmacy;
1588 (B) for a pharmacy medical provider licensed under Title 58, Chapter 67, Utah Medical
1589 Practice Act, the Physicians Licensing Board; and
1590 (C) for a pharmacy medical provider licensed under Title 58, Chapter 68, Utah
1591 Osteopathic Medical Practice Act, the Osteopathic Physician and Surgeon's Licensing Board.
1592 (c) The department may, in consultation with the Division of Professional Licensing,
1593 develop the continuing education described in this Subsection (3).
1594 (d) The continuing education described in this Subsection (3) may discuss:
1595 (i) the provisions of this chapter;
1596 (ii) general information about medical cannabis under federal and state law;
1597 (iii) the latest scientific research on the endocannabinoid system and medical cannabis,
1598 including risks and benefits;
1599 (iv) recommendations for medical cannabis as it relates to the continuing care of a
1600 patient in pain management, risk management, potential addiction, and palliative care; or
1601 (v) best practices for recommending the form and dosage of a medical cannabis
1602 product based on the qualifying condition underlying a medical cannabis recommendation.
1603 (4) (a) A pharmacy medical provider registration card expires two years after the day
1604 on which the department issues or renews the card.
1605 (b) A pharmacy medical provider may renew the provider's registration card if the
1606 provider:
1607 (i) is eligible for a pharmacy medical provider registration card under this section;
1608 (ii) certifies to the department in a renewal application that the information in

1609 Subsection (2)(a) is accurate or updates the information;
1610 (iii) submits a report detailing the completion of the continuing education requirement
1611 described in Subsection (3); and
1612 (iv) pays to the department a renewal fee in an amount that:
1613 (A) subject to Subsection 26-61a-109(5), the department sets in accordance with
1614 Section 63J-1-504; and
1615 (B) may not exceed the cost of the relatively lower administrative burden of renewal in
1616 comparison to the original application process.
1617 (5) (a) Except as provided in Subsection (5)(b), a person may not advertise that the
1618 person or another person dispenses medical cannabis.
1619 (b) Notwithstanding Subsection (5)(a) and subject to Section 26-61a-116, a registered
1620 pharmacy medical provider may advertise the following:
1621 (i) a green cross;
1622 (ii) that the person is registered as a pharmacy medical provider and dispenses medical
1623 cannabis; or
1624 (iii) a scientific study regarding medical cannabis use.
1625 Section 15. Section 26-61a-501 is amended to read:
1626 **26-61a-501. Operating requirements -- General.**
1627 (1) (a) A medical cannabis pharmacy shall operate:
1628 (i) at the physical address provided to the department under Section 26-61a-301; and
1629 (ii) in accordance with the operating plan provided to the department under Section
1630 26-61a-301 and, if applicable, Section 26-61a-304.
1631 (b) A medical cannabis pharmacy shall notify the department before a change in the
1632 medical cannabis pharmacy's physical address or operating plan.
1633 (2) An individual may not enter a medical cannabis pharmacy unless the individual:
1634 (a) is at least 18 years old or is an emancipated minor under Section 80-7-105; and
1635 (b) except as provided in Subsection (4):
1636 (i) possesses a valid:
1637 (A) medical cannabis pharmacy agent registration card;
1638 (B) pharmacy medical provider registration card; or
1639 (C) medical cannabis card;

(ii) is an employee of the department or the Department of Agriculture and Food performing an inspection under Section 26-61a-504; or

(iii) is another individual as the department provides.

(3) A medical cannabis pharmacy may not employ an individual who is younger than 21 years old.

(4) Notwithstanding Subsection (2)(a), a medical cannabis pharmacy may authorize an individual who is not a medical cannabis pharmacy agent or pharmacy medical provider to access the medical cannabis pharmacy if the medical cannabis pharmacy tracks and monitors the individual at all times while the individual is at the medical cannabis pharmacy and maintains a record of the individual's access.

(5) A medical cannabis pharmacy shall operate in a facility that has:

(a) a single, secure public entrance;

(b) a security system with a backup power source that:

(i) detects and records entry into the medical cannabis pharmacy; and

(ii) provides notice of an unauthorized entry to law enforcement when the medical cannabis pharmacy is closed; and

(c) a lock on each area where the medical cannabis pharmacy stores cannabis or a cannabis product.

(6) A medical cannabis pharmacy shall post, both clearly and conspicuously in the medical cannabis pharmacy, the limit on the purchase of cannabis described in Subsection 26-61a-502(2).

(7) Except for an emergency situation described in Subsection 26-61a-201(3)(c), a medical cannabis pharmacy may not allow any individual to consume cannabis on the property or premises of the medical cannabis pharmacy.

(8) A medical cannabis pharmacy may not sell cannabis or a cannabis product without first indicating on the cannabis or cannabis product label the name of the medical cannabis pharmacy.

(9) (a) Each medical cannabis pharmacy shall retain in the pharmacy's records the following information regarding each recommendation underlying a transaction:

(i) the recommending medical provider's name, address, and telephone number;

(ii) the patient's name and address;

1671 (iii) the date of issuance;

1672 (iv) directions of use and dosing guidelines or an indication that the recommending
1673 medical provider did not recommend specific directions of use or dosing guidelines; and

1674 (v) if the patient did not complete the transaction, the name of the medical cannabis
1675 cardholder who completed the transaction.

1676 (b) (i) Except as provided in Subsection (9)(b)(iii), a medical cannabis pharmacy may
1677 not sell medical cannabis unless the medical cannabis has a label securely affixed to the
1678 container indicating the following minimum information:

1679 (A) the name, address, and telephone number of the medical cannabis pharmacy;

1680 (B) the unique identification number that the medical cannabis pharmacy assigns;

1681 (C) the date of the sale;

1682 (D) the name of the patient;

1683 (E) the name of the recommending medical provider who recommended the medical
1684 cannabis treatment;

1685 (F) directions for use and cautionary statements, if any;

1686 (G) the amount dispensed and the cannabinoid content;

1687 (H) the suggested use date;

1688 (I) for unprocessed cannabis flower, the legal use termination date; and

1689 (J) any other requirements that the department determines, in consultation with the
1690 Division of Professional Licensing and the Board of Pharmacy.

1691 (ii) A medical cannabis pharmacy is exempt from the requirement to provide the
1692 following information under Subsection (9)(b)(i) if the information is already provided on the
1693 product label that a cannabis production establishment affixes:

1694 (A) a unique identification number;

1695 (B) directions for use and cautionary statements;

1696 (C) amount and cannabinoid content; and

1697 (D) a suggested use date.

1698 (iii) If the size of a medical cannabis container does not allow sufficient space to
1699 include the labeling requirements described in Subsection (9)(b)(i), the medical cannabis
1700 pharmacy may provide the following information described in Subsection (9)(b)(i) on a
1701 supplemental label attached to the container or an informational enclosure that accompanies the

1702 container:

1703 (A) the cannabinoid content;

1704 (B) the suggested use date; and

1705 (C) any other requirements that the department determines.

1706 (iv) A medical cannabis pharmacy may sell medical cannabis to another medical

1707 cannabis pharmacy without a label described in Subsection (9)(b)(i).

1708 (10) A pharmacy medical provider or medical cannabis pharmacy agent shall:

1709 (a) upon receipt of an order from a limited medical provider in accordance with

1710 Subsections 26-61a-106(1)(b) through (d):

1711 (i) for a written order or an electronic order under circumstances that the department

1712 determines, contact the limited medical provider or the limited medical provider's office to

1713 verify the validity of the recommendation; and

1714 (ii) for an order that the pharmacy medical provider or medical cannabis pharmacy

1715 agent verifies under Subsection (10)(a)(i) or an electronic order that is not subject to

1716 verification under Subsection (10)(a)(i), enter the limited medical provider's recommendation

1717 or renewal, including any associated directions of use, dosing guidelines, or caregiver

1718 indication, in the state electronic verification system;

1719 (b) in processing an order for a holder of a conditional medical cannabis card described

1720 in Subsection 26-61a-201(1)(b) that appears irregular or suspicious in the judgment of the

1721 pharmacy medical provider or medical cannabis pharmacy agent, contact the recommending

1722 medical provider or the recommending medical provider's office to verify the validity of the

1723 recommendation before processing the cardholder's order;

1724 (c) unless the medical cannabis cardholder has had a consultation under Subsection

1725 26-61a-502(4), ~~or (5),~~ verbally offer to a medical cannabis cardholder at the time of a

1726 purchase of cannabis, a cannabis product, or a medical cannabis device, personal counseling

1727 with the pharmacy medical provider; and

1728 (d) provide a telephone number or website by which the cardholder may contact a

1729 pharmacy medical provider for counseling.

1730 (11) (a) A medical cannabis pharmacy may create a medical cannabis disposal program

1731 that allows an individual to deposit unused or excess medical cannabis, cannabis residue from a

1732 medical cannabis device, or medical cannabis product in a locked box or other secure

receptacle within the medical cannabis pharmacy.

(b) A medical cannabis pharmacy with a disposal program described in Subsection (11)(a) shall ensure that only a medical cannabis pharmacy agent or pharmacy medical provider can access deposited medical cannabis or medical cannabis products.

(c) A medical cannabis pharmacy shall dispose of any deposited medical cannabis or medical cannabis products by:

(i) rendering the deposited medical cannabis or medical cannabis products unusable and unrecognizable before transporting deposited medical cannabis or medical cannabis products from the medical cannabis pharmacy; and

(ii) disposing of the deposited medical cannabis or medical cannabis products in accordance with:

(A) federal and state law, rules, and regulations related to hazardous waste;

(B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;

(C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and

(D) other regulations that the department makes in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.

(12) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, protocols for a recall of cannabis and cannabis products by a medical cannabis pharmacy.

Section 16. Section **26-61a-502** is amended to read:

26-61a-502. Dispensing -- Amount a medical cannabis pharmacy may dispense -- Reporting -- Form of cannabis or cannabis product.

(1) (a) A medical cannabis pharmacy may not sell a product other than, subject to this chapter:

(i) cannabis in a medicinal dosage form that the medical cannabis pharmacy acquired from another medical cannabis pharmacy or a cannabis processing facility that is licensed under Section [4-41a-201](#);

(ii) a cannabis product in a medicinal dosage form that the medical cannabis pharmacy acquired from another medical cannabis pharmacy or a cannabis processing facility that is licensed under Section [4-41a-201](#);

(iii) a medical cannabis device; or

- 1764 (iv) educational material related to the medical use of cannabis.
- 1765 (b) A medical cannabis pharmacy may only sell an item listed in Subsection (1)(a) to
1766 an individual with:
- 1767 (i) (A) a medical cannabis card;
- 1768 (B) a department registration described in Section 26-61a-201(10); and
- 1769 (ii) a corresponding ~~[valid form of]~~ government issued photo identification.
- 1770 (c) Notwithstanding Subsection (1)(a), a medical cannabis pharmacy may not sell a
1771 cannabis-based drug that the United States Food and Drug Administration has approved.
- 1772 (d) Notwithstanding Subsection (1)(b), a medical cannabis pharmacy may not sell a
1773 medical cannabis device or medical cannabis product to an individual described in Subsection
1774 26-61a-201(2)(a)(i)(B) or to a minor described in Subsection 26-61a-201(2)(c) unless the
1775 individual or minor has the approval of the Compassionate Use Board in accordance with
1776 Subsection 26-61a-105(5)(b).
- 1777 (2) A medical cannabis pharmacy:
- 1778 (a) may dispense to a medical cannabis cardholder, in any one 28-day period, up to the
1779 legal dosage limit of:
- 1780 (i) unprocessed cannabis that:
- 1781 (A) is in a medicinal dosage form; and
- 1782 (B) carries a label clearly displaying the amount of tetrahydrocannabinol and
1783 cannabidiol in the cannabis; and
- 1784 (ii) a cannabis product that is in a medicinal dosage form; and
- 1785 (b) may not dispense:
- 1786 (i) more medical cannabis than described in Subsection (2)(a); or
- 1787 (ii) to an individual whose recommending medical provider did not recommend
1788 directions of use and dosing guidelines, until the individual consults with the pharmacy
1789 medical provider in accordance with Subsection (4), any medical cannabis.
- 1790 (3) An individual with a medical cannabis card:
- 1791 (a) may purchase, in any one 28-day period, up to the legal dosage limit of:
- 1792 (i) unprocessed cannabis in a medicinal dosage form; and
- 1793 (ii) a cannabis product in a medicinal dosage form;
- 1794 (b) may not purchase:

1795 (i) more medical cannabis than described in Subsection (3)(a); or
1796 (ii) if the relevant recommending medical provider did not recommend directions of
1797 use and dosing guidelines, until the individual consults with the pharmacy medical provider in
1798 accordance with Subsection (4), any medical cannabis; and

1799 (c) may not use a route of administration that the relevant recommending medical
1800 provider or the pharmacy medical provider, in accordance with Subsection (4) or (5), has not
1801 recommended.

1802 (4) If a recommending medical provider recommends treatment with medical cannabis
1803 but wishes for the pharmacy medical provider to determine directions of use and dosing
1804 guidelines:

1805 (a) the recommending medical provider shall provide to the pharmacy medical
1806 provider, either through the state electronic verification system or through a medical cannabis
1807 pharmacy's recording of a recommendation under the order of a limited medical provider, any
1808 of the following information that the recommending medical provider feels would be needed to
1809 provide appropriate directions of use and dosing guidelines:

1810 (i) information regarding the qualifying condition underlying the recommendation;
1811 (ii) information regarding prior treatment attempts with medical cannabis; and
1812 (iii) portions of the patient's current medication list; and

1813 (b) before the relevant medical cannabis cardholder may obtain medical cannabis, the
1814 pharmacy medical provider shall:

1815 (i) review pertinent medical records, including the recommending medical provider
1816 documentation described in Subsection (4)(a); and

1817 (ii) ~~[unless the pertinent medical records show directions of use and dosing guidelines~~
1818 ~~from a state central patient portal medical provider in accordance with Subsection (5),]~~ after
1819 completing the review described in Subsection (4)(b)(i) and consulting with the recommending
1820 medical provider as needed, determine the best course of treatment through consultation with
1821 the cardholder regarding:

1822 (A) the patient's qualifying condition underlying the recommendation from the
1823 recommending medical provider;

1824 (B) indications for available treatments;

1825 (C) directions of use and dosing guidelines; and

(D) potential adverse reactions.

~~[(5)(a) A state central patient portal medical provider may provide the consultation and make the determination described in Subsection (4)(b) for a medical cannabis patient cardholder regarding an electronic order that the state central patient portal facilitates.]~~

~~[(b) The state central patient portal medical provider described in Subsection (5)(a) shall document the directions of use and dosing guidelines, determined under Subsection (5)(a) in the pertinent medical records.]~~

~~[(6)]~~ (5) (a) A medical cannabis pharmacy shall:

(i) (A) access the state electronic verification system before dispensing cannabis or a cannabis product to a medical cannabis cardholder in order to determine if the cardholder or, where applicable, the associated patient has met the maximum amount of medical cannabis described in Subsection (2); and

(B) if the verification in Subsection ~~[(6)(a)(i)]~~ (5)(a)(i) indicates that the individual has met the maximum amount described in Subsection (2), decline the sale, and notify the recommending medical provider who made the underlying recommendation;

(ii) submit a record to the state electronic verification system each time the medical cannabis pharmacy dispenses medical cannabis to a medical cannabis cardholder;

(iii) ensure that the pharmacy medical provider who is a licensed pharmacist reviews each medical cannabis transaction before dispensing the medical cannabis to the cardholder in accordance with pharmacy practice standards;

(iv) package any medical cannabis that is in a container that:

(A) complies with Subsection 4-41a-602(1)(b) or, if applicable, provisions related to a container for unprocessed cannabis flower in the definition of "medicinal dosage form" in Section 26-61a-102;

(B) is tamper-resistant and tamper-evident; and

(C) provides an opaque bag or box for the medical cannabis cardholder's use in transporting the container in public; and

(v) for a product that is a cube that is designed for ingestion through chewing or holding in the mouth for slow dissolution, include a separate, off-label warning about the risks of over-consumption.

(b) A medical cannabis cardholder transporting or possessing the container described

in Subsection ~~[(6)(a)(iv)]~~ (5)(a)(iv) in public shall keep the container within the opaque bag or box that the medical cannabis pharmacist provides.

~~[(7)]~~ (6) (a) Except as provided in Subsection ~~[(7)(b)]~~ (6)(b), a medical cannabis pharmacy may not sell medical cannabis in the form of a cigarette or a medical cannabis device that is intentionally designed or constructed to resemble a cigarette.

(b) A medical cannabis pharmacy may sell a medical cannabis device that warms cannabis material into a vapor without the use of a flame and that delivers cannabis to an individual's respiratory system.

~~[(8)]~~ (7) (a) A medical cannabis pharmacy may not give, at no cost, a product that the medical cannabis pharmacy is allowed to sell under Subsection (1)(a)(i), (ii), or (iii).

(b) A medical cannabis pharmacy may give, at no cost, educational material related to the medical use of cannabis.

~~[(9)]~~ (8) The department may impose a uniform fee on each medical cannabis transaction in a medical cannabis pharmacy in an amount that, subject to Subsection [26-61a-109\(5\)](#), the department sets in accordance with Section [63J-1-504](#).

~~[(10)]~~ (9) A medical cannabis pharmacy may purchase and store medical cannabis devices regardless of whether the seller has a cannabis-related license under this title or Title 4, Chapter 41a, Cannabis Production Establishments.

Section 17. Section **26-61a-503** is amended to read:

26-61a-503. Partial filling.

(1) As used in this section, "partially fill" means to provide less than the full amount of cannabis or cannabis product that the recommending medical provider recommends, if the recommending medical provider recommended specific dosing ~~[parameters]~~ guidelines.

(2) A pharmacy medical provider may partially fill a recommendation for a medical cannabis treatment at the request of the recommending medical provider who issued the medical cannabis treatment recommendation or the medical cannabis cardholder.

(3) The department shall make rules, in collaboration with the Division of Professional Licensing and the Board of Pharmacy and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, specifying how to record the date, quantity supplied, and quantity remaining of a partially filled medical cannabis treatment recommendation.

(4) A pharmacy medical provider who is a pharmacist may, upon the request of a

medical cannabis cardholder, determine different dosing [~~parameters~~] guidelines, subject to the dosing limits in Subsection 26-61a-502(2), to fill the quantity remaining of a partially filled medical cannabis treatment recommendation if:

(a) the pharmacy medical provider determined dosing [~~parameters~~] guidelines for the partial fill under Subsection 26-61a-502(4) [~~or (5)~~]; and

(b) the medical cannabis cardholder reports that:

(i) the partial fill did not substantially affect the qualifying condition underlying the medical cannabis recommendation; or

(ii) the patient experienced an adverse reaction to the partial fill or was otherwise unable to successfully use the partial fill.

Section 18. Section **26-61a-505** is amended to read:

26-61a-505. Advertising.

(1) Except as provided in this section, a person may not advertise in any medium regarding a medical cannabis pharmacy or the dispensing of medical cannabis within the state.

(2) [~~Subject to Section 26-61a-116, a~~] A medical cannabis pharmacy may:

(a) advertise an employment opportunity at the medical cannabis pharmacy;

(b) notwithstanding any municipal or county ordinance prohibiting signage, use signage on the outside of the medical cannabis pharmacy that:

(i) includes only:

(A) in accordance with Subsection [~~26-61a-116(4)~~] 26-61a-116(3), the medical cannabis pharmacy's name, logo, and hours of operation; and

(B) a green cross; and

(ii) complies with local ordinances regulating signage;

(c) advertise in any medium:

(i) the pharmacy's name and logo;

(ii) the location and hours of operation of the medical cannabis pharmacy;

(iii) a service available at the medical cannabis pharmacy;

(iv) personnel affiliated with the medical cannabis pharmacy;

(v) whether the medical cannabis pharmacy is licensed as a home delivery medical cannabis pharmacy;

(vi) best practices that the medical cannabis pharmacy upholds; and

(vii) educational material related to the medical use of cannabis, as defined by the department;

(d) hold an educational event for the public or medical providers in accordance with Subsection (3) and the rules described in Subsection (4); ~~and~~

(e) maintain on the medical cannabis pharmacy's website non-promotional information regarding the medical cannabis pharmacy's inventory~~[-];~~ or

(f) engage in targeted marketing, as determined by the department through rule, for advertising a particular medical cannabis product, medical cannabis device, or medical cannabis brand.

(3) A medical cannabis pharmacy may not include in an educational event described in Subsection (2)(d):

(a) any topic that conflicts with this chapter or Title 4, Chapter 41a, Cannabis Production Establishments;

(b) any gift items or merchandise other than educational materials, as those terms are defined by the department;

(c) any marketing for a specific product from the medical cannabis pharmacy or any other statement, claim, or information that would violate the federal Food, Drug, and Cosmetic Act, 21 U.S.C. Sec. 301, et seq.; or

(d) a presenter other than the following:

(i) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;

(ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse Practice Act;

(iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act;

(iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant Act;

(v) a medical practitioner, similar to the practitioners described in this Subsection (3)(d)(v), who is licensed in another state or country;

(vi) a state employee; or

(vii) if the presentation relates to a cannabis topic other than medical treatment or medical conditions, an individual whom the department approves based on the individual's

1950 background and credentials in the presented topic.

1951 (4) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1952 Administrative Rulemaking Act, to define:

1953 (a) the educational material described in Subsection (2)(c)(vii); and

1954 (b) the elements of and restrictions on the educational event described in Subsection
1955 (3), including:

1956 (i) a minimum age of 21 years old for attendees; and

1957 (ii) an exception to the minimum age for a medical cannabis patient cardholder who is
1958 at least 18 years old.

1959 Section 19. Section **26-61a-506** is amended to read:

1960 **26-61a-506. Medical cannabis transportation.**

1961 (1) Only the following individuals may transport medical cannabis under this chapter:

1962 (a) a registered medical cannabis pharmacy agent;

1963 (b) a registered medical cannabis courier agent;

1964 (c) a registered pharmacy medical provider; or

1965 (d) a medical cannabis cardholder who is transporting a medical cannabis treatment
1966 that the cardholder is authorized to transport.

1967 (2) Except for an individual with a valid medical cannabis card under this chapter who
1968 is transporting a medical cannabis treatment that the cardholder is authorized to transport, an
1969 individual described in Subsection (1) shall possess a transportation manifest that:

1970 (a) includes a unique identifier that links the cannabis or cannabis product to a relevant
1971 inventory control system;

1972 (b) includes origin and destination information for the medical cannabis that the
1973 individual is transporting; and

1974 (c) identifies the departure and arrival times and locations of the individual
1975 transporting the medical cannabis.

1976 (3) (a) In addition to the requirements in Subsections (1) and (2), the department may
1977 establish by rule, in collaboration with the Division of Professional Licensing and the Board of
1978 Pharmacy and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,
1979 requirements for transporting medical cannabis to ensure that the medical cannabis remains
1980 safe for human consumption.

(b) The transportation described in Subsection (1)(a) is limited to transportation between a medical cannabis pharmacy and:

- (i) another medical cannabis pharmacy; or
- (ii) for a medical cannabis shipment, a ~~[medical cannabis cardholder's home]~~ delivery address.

(4) (a) It is unlawful for an individual described in Subsection (1) to make a transport described in this section with a manifest that does not meet the requirements of this section.

(b) Except as provided in Subsection (4)(d), an individual who violates Subsection (4)(a) is:

- (i) guilty of an infraction; and
 - (ii) subject to a \$100 fine.
- (c) An individual who is guilty of a violation described in Subsection (4)(b) is not guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct underlying the violation described in Subsection (4)(b).

(d) If the individual described in Subsection (4)(a) is transporting more medical cannabis than the manifest identifies, except for a de minimis administrative error:

- (i) this chapter does not apply; and
- (ii) the individual is subject to penalties under Title 58, Chapter 37, Utah Controlled Substances Act.

(5) An individual other than an individual described in Subsection (1) may transport a medical cannabis device within the state if the transport does not also contain medical cannabis.

Section 20. Section **26-61a-601** is amended to read:

26-61a-601. State central patient portal -- Department duties.

(1) On or before July 1, 2020, the department shall establish or contract to establish, in accordance with Title 63G, Chapter 6a, Utah Procurement Code, a state central patient portal as described in this section.

(2) The state central patient portal shall:

- (a) authenticate each user to ensure the user is a valid medical cannabis patient cardholder;
- (b) allow a medical cannabis patient cardholder to:

(i) obtain and download the cardholder's medical cannabis card;

(ii) review the cardholder's medical cannabis purchase history; and

(iii) manage the cardholder's personal information, including withdrawing consent for the use of the cardholder's information for a study described in Subsection 26-61a-201(12);

(c) if the cardholder's recommending medical provider recommended the use of medical cannabis without providing directions of use and dosing guidelines and the cardholder has not yet received the counseling or consultation required in Subsection 26-61a-502(4):

(i) alert the cardholder of the outstanding need for consultation; and

(ii) provide the cardholder with access to the contact information for ~~[each state central patient portal medical provider and]~~ each pharmacy medical provider;

(d) except as provided in Subsection (2)(e), facilitate an electronic medical cannabis order:

(i) to a home delivery medical cannabis pharmacy for a medical cannabis shipment; or

(ii) to a medical cannabis pharmacy for a medical cannabis cardholder to obtain in person from the pharmacy;

(e) prohibit a patient from completing an electronic medical cannabis order described in Subsection (2)(d) if the purchase would exceed the limitations described in Subsection 26-61a-502(2)(a) or (b);

(f) provide educational information to medical cannabis patient cardholders regarding the state's medical cannabis laws and regulatory programs and other relevant information regarding medical cannabis; and

(g) allow the patient to designate up to two caregivers who may receive a medical cannabis caregiver card to purchase and transport medical cannabis on behalf of the patient in accordance with this chapter.

(3) The department may make rules in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to implement the state central patient portal.

Section 21. Section **26-61a-604** is amended to read:

26-61a-604. Home delivery of medical cannabis shipments -- Medical cannabis couriers -- License.

(1) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to ensure the safety, security, and efficiency of a home

delivery medical cannabis pharmacy's fulfillment of electronic medical cannabis orders that the state central patient portal facilitates, including rules regarding the safe and controlled delivery of medical cannabis shipments.

(2) A person may not operate as a medical cannabis courier without a license that the department issues under this section.

(3) (a) Subject to Subsections (5) and (6), the department shall issue a license to operate as a medical cannabis courier to an applicant who is eligible for a license under this section.

(b) An applicant is eligible for a license under this section if the applicant submits to the department:

(i) the name and address of an individual who:

(A) has a financial or voting interest of [2] 10% or greater in the proposed medical cannabis pharmacy; or

(B) has the power to direct or cause the management or control of a proposed cannabis production establishment;

(ii) an operating plan that includes operating procedures to comply with the operating requirements for a medical cannabis courier described in this chapter; and

(iii) an application fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504.

(4) If the department determines that an applicant is eligible for a license under this section, the department shall:

(a) charge the applicant an initial license fee in an amount that, subject to Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504; and

(b) notify the Department of Public Safety of the license approval and the names of each individual described in Subsection (3)(b)(ii).

(5) The department may not issue a license to operate as a medical cannabis courier to an applicant if an individual described in Subsection (3)(b)(ii):

(a) has been convicted under state or federal law of:

(i) a felony; or

(ii) after September 23, 2019, a misdemeanor for drug distribution; or

(b) is younger than 21 years old.

2074 (6) The department may revoke a license under this part if:
2075 (a) the medical cannabis courier does not begin operations within one year after the day
2076 on which the department issues the initial license;
2077 (b) the medical cannabis courier makes the same violation of this chapter three times;
2078 (c) an individual described in Subsection (3)(b)(ii) is convicted, while the license is
2079 active, under state or federal law of:
2080 (i) a felony; or
2081 (ii) after September 23, 2019, a misdemeanor for drug distribution; or
2082 (d) after a change of ownership described in Subsection (15)(c), the department
2083 determines that the medical cannabis courier no longer meets the minimum standards for
2084 licensure and operation of the medical cannabis courier described in this chapter.
2085 (7) The department shall deposit the proceeds of a fee imposed by this section in the
2086 Qualified Patient Enterprise Fund.
2087 (8) The department shall begin accepting applications under this section on or before
2088 July 1, 2020.
2089 (9) The department's authority to issue a license under this section is plenary and is not
2090 subject to review.
2091 (10) Each applicant for a license as a medical cannabis courier shall submit, at the time
2092 of application, from each individual who has a financial or voting interest of [2] 10% or greater
2093 in the applicant or who has the power to direct or cause the management or control of the
2094 applicant:
2095 (a) a fingerprint card in a form acceptable to the Department of Public Safety;
2096 (b) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the
2097 registration of the individual's fingerprints in the Federal Bureau of Investigation Next
2098 Generation Identification System's Rap Back Service; and
2099 (c) consent to a fingerprint background check by:
2100 (i) the Bureau of Criminal Identification; and
2101 (ii) the Federal Bureau of Investigation.
2102 (11) The Bureau of Criminal Identification shall:
2103 (a) check the fingerprints the applicant submits under Subsection (10) against the
2104 applicable state, regional, and national criminal records databases, including the Federal

2105 Bureau of Investigation Next Generation Identification System;
2106 (b) report the results of the background check to the department;
2107 (c) maintain a separate file of fingerprints that applicants submit under Subsection (10)
2108 for search by future submissions to the local and regional criminal records databases, including
2109 latent prints;
2110 (d) request that the fingerprints be retained in the Federal Bureau of Investigation Next
2111 Generation Identification System's Rap Back Service for search by future submissions to
2112 national criminal records databases, including the Next Generation Identification System and
2113 latent prints; and
2114 (e) establish a privacy risk mitigation strategy to ensure that the department only
2115 receives notifications for an individual with whom the department maintains an authorizing
2116 relationship.
2117 (12) The department shall:
2118 (a) assess an individual who submits fingerprints under Subsection (10) a fee in an
2119 amount that the department sets in accordance with Section 63J-1-504 for the services that the
2120 Bureau of Criminal Identification or another authorized agency provides under this section; and
2121 (b) remit the fee described in Subsection (12)(a) to the Bureau of Criminal
2122 Identification.
2123 (13) The department shall renew a license under this section every year if, at the time
2124 of renewal:
2125 (a) the licensee meets the requirements of this section; and
2126 (b) the licensee pays the department a license renewal fee in an amount that, subject to
2127 Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504.
2128 (14) A person applying for a medical cannabis courier license shall submit to the
2129 department a proposed operating plan that complies with this section and that includes:
2130 (a) a description of the physical characteristics of any proposed facilities, including a
2131 floor plan and an architectural elevation, and delivery vehicles;
2132 (b) a description of the credentials and experience of each officer, director, or owner of
2133 the proposed medical cannabis courier;
2134 (c) the medical cannabis courier's employee training standards;
2135 (d) a security plan; and

(e) storage and delivery protocols, both short and long term, to ensure that medical cannabis shipments are stored and delivered in a manner that is sanitary and preserves the integrity of the cannabis.

(15) (a) A medical cannabis courier license is not transferrable or assignable.

(b) A medical cannabis courier shall report in writing to the department no later than 10 business days before the date of any change of ownership of the medical cannabis courier.

(c) If the ownership of a medical cannabis courier changes by 50% or more:

(i) concurrent with the report described in Subsection (15)(b), the medical cannabis courier shall submit a new application described in Subsection (3)(b);

(ii) within 30 days of the submission of the application, the department shall:

(A) conduct an application review; and

(B) award a license to the medical cannabis courier for the remainder of the term of the medical cannabis courier's license before the ownership change if the medical cannabis courier meets the minimum standards for licensure and operation of the medical cannabis courier described in this chapter; and

(iii) if the department approves the license application, notwithstanding Subsection (4), the medical cannabis courier shall pay a license fee that the department sets in accordance with Section 63J-1-504 in an amount that covers the board's cost of conducting the application review.

(16) (a) Except as provided in Subsection ~~[(15)(b)]~~ (16)(b), a person may not advertise regarding the transportation of medical cannabis.

(b) Notwithstanding Subsection (15)(a) and subject to Section 26-61a-116, a licensed home delivery medical cannabis pharmacy or a licensed medical cannabis courier may advertise:

(i) a green cross;

(ii) the pharmacy's or courier's name and logo; and

(iii) that the pharmacy or courier is licensed to transport medical cannabis shipments.

Section 22. Section 26-61a-606 is amended to read:

26-61a-606. Medical cannabis courier agent -- Background check -- Registration card -- Rebuttable presumption.

(1) An individual may not serve as a medical cannabis courier agent unless:

2167 (a) the individual is an employee of a licensed medical cannabis courier; and
2168 (b) the department registers the individual as a medical cannabis courier agent.

2169 (2) (a) The department shall, within 15 days after the day on which the department
2170 receives a complete application from a medical cannabis courier on behalf of a medical
2171 cannabis courier agent, register and issue a medical cannabis courier agent registration card to
2172 the prospective agent if the medical cannabis courier:

2173 (i) provides to the department:

2174 (A) the prospective agent's name and address;

2175 (B) the name and address of the medical cannabis courier;

2176 (C) the name and address of each home delivery medical cannabis pharmacy with
2177 which the medical cannabis courier contracts to deliver medical cannabis shipments; and

2178 (D) the submission required under Subsection (2)(b);

2179 (ii) as reported under Subsection (2)(c), has not been convicted under state or federal
2180 law of:

2181 (A) a felony; or

2182 (B) after December 3, 2018, a misdemeanor for drug distribution; and

2183 (iii) pays the department a fee in an amount that, subject to Subsection 26-61a-109(5),
2184 the department sets in accordance with Section 63J-1-504.

2185 (b) Except for an applicant reapplying for a medical cannabis courier agent registration
2186 card within less than one year after the expiration of the applicant's previous medical cannabis
2187 courier agent registration card, each prospective agent described in Subsection (2)(a) shall:

2188 (i) submit to the department:

2189 (A) a fingerprint card in a form acceptable to the Department of Public Safety; and

2190 (B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the
2191 registration of the prospective agent's fingerprints in the Federal Bureau of Investigation Next
2192 Generation Identification System's Rap Back Service; and

2193 (ii) consent to a fingerprint background check by:

2194 (A) the Bureau of Criminal Identification; and

2195 (B) the Federal Bureau of Investigation.

2196 (c) The Bureau of Criminal Identification shall:

2197 (i) check the fingerprints the prospective agent submits under Subsection (2)(b) against

2198 the applicable state, regional, and national criminal records databases, including the Federal
2199 Bureau of Investigation Next Generation Identification System;

2200 (ii) report the results of the background check to the department;

2201 (iii) maintain a separate file of fingerprints that prospective agents submit under
2202 Subsection (2)(b) for search by future submissions to the local and regional criminal records
2203 databases, including latent prints;

2204 (iv) request that the fingerprints be retained in the Federal Bureau of Investigation Next
2205 Generation Identification System's Rap Back Service for search by future submissions to
2206 national criminal records databases, including the Next Generation Identification System and
2207 latent prints; and

2208 (v) establish a privacy risk mitigation strategy to ensure that the department only
2209 receives notifications for an individual with whom the department maintains an authorizing
2210 relationship.

2211 (d) The department shall:

2212 (i) assess an individual who submits fingerprints under Subsection (2)(b) a fee in an
2213 amount that the department sets in accordance with Section 63J-1-504 for the services that the
2214 Bureau of Criminal Identification or another authorized agency provides under this section; and

2215 (ii) remit the fee described in Subsection (2)(d)(i) to the Bureau of Criminal
2216 Identification.

2217 (3) The department shall designate on an individual's medical cannabis courier agent
2218 registration card the name of the medical cannabis pharmacy where the individual is registered
2219 as an agent and each home delivery medical cannabis courier for which the medical cannabis
2220 courier delivers medical cannabis shipments.

2221 (4) (a) A medical cannabis courier agent shall comply with a certification standard that
2222 the department develops, in collaboration with the Division of Professional Licensing and the
2223 Board of Pharmacy, or a third-party certification standard that the department designates by
2224 rule in collaboration with the Division of Professional Licensing and the Board of Pharmacy
2225 and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.

2226 (b) The department shall ensure that the certification standard described in Subsection
2227 (4)(a) includes training in:

2228 (i) Utah medical cannabis law;

2229 (ii) the medical cannabis shipment process; and
2230 (iii) medical cannabis courier agent best practices.

2231 (5) (a) A medical cannabis courier agent registration card expires two years after the
2232 day on which the department issues or renews the card.

2233 (b) A medical cannabis courier agent may renew the agent's registration card if the
2234 agent:

2235 (i) is eligible for a medical cannabis courier agent registration card under this section;
2236 (ii) certifies to the department in a renewal application that the information in
2237 Subsection (2)(a) is accurate or updates the information; and
2238 (iii) pays to the department a renewal fee in an amount that:

2239 (A) subject to Subsection 26-61a-109(5), the department sets in accordance with
2240 Section 63J-1-504; and

2241 (B) may not exceed the cost of the relatively lower administrative burden of renewal in
2242 comparison to the original application process.

2243 (6) The department may revoke or refuse to issue or renew the medical cannabis
2244 courier agent registration card of an individual who:

2245 (a) violates the requirements of this chapter; or
2246 (b) is convicted under state or federal law of:

2247 (i) a felony within the preceding 10 years; or
2248 (ii) after December 3, 2018, a misdemeanor for drug distribution.

2249 (7) A medical cannabis courier agent whom the department has registered under this
2250 section shall carry the agent's medical cannabis courier agent registration card with the agent at
2251 all times when:

2252 (a) the agent is on the premises of the medical cannabis courier, a medical cannabis
2253 pharmacy, or a ~~[medical cannabis cardholder's home]~~ delivery address; and
2254 (b) the agent is handling a medical cannabis shipment.

2255 (8) If a medical cannabis courier agent handling a medical cannabis shipment possesses
2256 the shipment in compliance with Subsection (7):

2257 (a) there is a rebuttable presumption that the agent possesses the shipment legally; and
2258 (b) there is no probable cause, based solely on the agent's possession of the medical
2259 cannabis shipment that the agent is engaging in illegal activity.

2260 (9) (a) A medical cannabis courier agent who violates Subsection (7) is:

2261 (i) guilty of an infraction; and

2262 (ii) subject to a \$100 fine.

2263 (b) An individual who is guilty of a violation described in Subsection (9)(a) is not
2264 guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct
2265 underlying the violation described in Subsection (9)(a).

2266 Section 23. Section **26-61a-607** is amended to read:

2267 **26-61a-607. Home delivery of medical cannabis shipments.**

2268 (1) An individual may not receive and a medical cannabis pharmacy agent or a medical
2269 cannabis courier agent may not deliver a medical cannabis shipment from a home delivery
2270 medical cannabis pharmacy unless:

2271 (a) the individual receiving the shipment presents:

2272 (i) a ~~[valid form of photo identification]~~ government issued photo identification; and

2273 (ii) (A) a valid medical cannabis card under the same name that appears on the ~~[valid~~
2274 ~~form of photo identification]~~ government issued photo identification; or

2275 (B) for a facility that a medical cannabis cardholder has designated as a caregiver under
2276 Subsection 26-61a-202(1)(b), evidence of the facility caregiver designation; and

2277 (b) the delivery occurs at:

2278 (i) the ~~[medical cannabis cardholder's home]~~ delivery address that is on file in the state
2279 electronic verification system; or

2280 (ii) the facility that the medical cannabis cardholder has designated as a caregiver under
2281 Subsection 26-61a-202(1)(b).

2282 (2) Before a medical cannabis pharmacy agent or a medical cannabis courier agent
2283 distributes a medical cannabis shipment to a medical cannabis cardholder, the agent shall:

2284 (a) verify the shipment information using the state electronic verification system;

2285 (b) ensure that the individual satisfies the identification requirements in Subsection (1);

2286 (c) verify that payment is complete; and

2287 (d) record the completion of the shipment transaction in a manner such that the
2288 delivery of the shipment will later be recorded within a reasonable period in the electronic
2289 verification system.

2290 (3) The medical cannabis courier shall:

2291 (a) (i) store each medical cannabis shipment in a secure manner until the recipient
2292 medical cannabis cardholder receives the shipment or the medical cannabis courier returns the
2293 shipment to the home delivery medical cannabis pharmacy in accordance with Subsection (4);
2294 and

2295 (ii) ensure that only a medical cannabis courier agent is able to access the medical
2296 cannabis shipment until the recipient medical cannabis cardholder receives the shipment;

2297 (b) return any undelivered medical cannabis shipment to the home delivery medical
2298 cannabis pharmacy, in accordance with Subsection (4), after the medical cannabis courier has
2299 possessed the shipment for 10 business days; and

2300 (c) return any medical cannabis shipment to the home delivery medical cannabis
2301 pharmacy, in accordance with Subsection (4), if a medical cannabis cardholder refuses to
2302 accept the shipment.

2303 (4) (a) If a medical cannabis courier or home delivery medical cannabis pharmacy
2304 agent returns an undelivered medical cannabis shipment that remains unopened, the home
2305 delivery medical cannabis pharmacy may repackage or otherwise reuse the shipment.

2306 (b) If a medical cannabis courier or home delivery medical cannabis pharmacy agent
2307 returns an undelivered or refused medical cannabis shipment under Subsection (3) that appears
2308 to be opened in any way, the home delivery medical cannabis pharmacy shall dispose of the
2309 shipment by:

2310 (i) rendering the shipment unusable and unrecognizable before transporting the
2311 shipment from the home delivery medical cannabis pharmacy; and

2312 (ii) disposing of the shipment in accordance with:

2313 (A) federal and state laws, rules, and regulations related to hazardous waste;

2314 (B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;

2315 (C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and

2316 (D) other regulations that the department makes in accordance with Title 63G, Chapter
2317 3, Utah Administrative Rulemaking Act.

2318 Section 24. Section **58-17b-502** is amended to read:

2319 **58-17b-502. Unprofessional conduct.**

2320 (1) "Unprofessional conduct" includes:

2321 (a) willfully deceiving or attempting to deceive the division, the board, or their agents

as to any relevant matter regarding compliance under this chapter;

(b) except as provided in Subsection (2):

(i) paying or offering rebates to practitioners or any other health care providers, or receiving or soliciting rebates from practitioners or any other health care provider; or

(ii) paying, offering, receiving, or soliciting compensation in the form of a commission, bonus, rebate, kickback, or split fee arrangement with practitioners or any other health care provider, for the purpose of obtaining referrals;

(c) misbranding or adulteration of any drug or device or the sale, distribution, or dispensing of any outdated, misbranded, or adulterated drug or device;

(d) engaging in the sale or purchase of drugs or devices that are samples or packages bearing the inscription "sample" or "not for resale" or similar words or phrases;

(e) except as provided in Section 58-17b-503, accepting back and redistributing any unused drug, or a part of it, after it has left the premises of a pharmacy;

(f) an act in violation of this chapter committed by a person for any form of compensation if the act is incidental to the person's professional activities, including the activities of a pharmacist, pharmacy intern, or pharmacy technician;

(g) violating:

(i) the federal Controlled Substances Act, Title II, P.L. 91-513;

(ii) Title 58, Chapter 37, Utah Controlled Substances Act; or

(iii) rules or regulations adopted under either act;

(h) requiring or permitting pharmacy interns or technicians to engage in activities outside the scope of practice for their respective license classifications, as defined in this chapter and division rules made in collaboration with the board, or beyond their scope of training and ability;

(i) administering:

(i) without appropriate training, as defined by rule;

(ii) without a physician's order, when one is required by law; and

(iii) in conflict with a practitioner's written guidelines or written protocol for administering;

(j) disclosing confidential patient information in violation of the provisions of the Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat.

2353 1936, as amended, or other applicable law;

2354 (k) engaging in the practice of pharmacy without a licensed pharmacist designated as
2355 the pharmacist-in-charge;

2356 (l) failing to report to the division any adverse action taken by another licensing
2357 jurisdiction, government agency, law enforcement agency, or court for conduct that in
2358 substance would be considered unprofessional conduct under this section;

2359 (m) as a pharmacist or pharmacy intern, compounding a prescription drug in a dosage
2360 form which is regularly and commonly available from a manufacturer in quantities and
2361 strengths prescribed by a practitioner;

2362 (n) failing to act in accordance with Title 26, Chapter 64, Family Planning Access Act,
2363 when dispensing a self-administered hormonal contraceptive under a standing order;

2364 (o) violating the requirements of Title 26, Chapter 61a, Utah Medical Cannabis Act; or

2365 (p) falsely making an entry in, or altering, a medical record with the intent to conceal:

2366 (i) a wrongful or negligent act or omission of an individual licensed under this chapter
2367 or an individual under the direction or control of an individual licensed under this chapter; or

2368 (ii) conduct described in Subsections (1)(a) through (o) or Subsection 58-1-501(1).

2369 (2) Subsection (1)(b) does not apply to:

2370 (a) giving or receiving a price discount based on purchase volume;

2371 (b) passing along a pharmaceutical manufacturer's rebate; or

2372 (c) providing compensation for services to a veterinarian.

2373 (3) "Unprofessional conduct" does not include, in accordance with Title 26, Chapter

2374 61a, Utah Medical Cannabis Act~~[-(a)]~~, when registered as a pharmacy medical provider, as

2375 that term is defined in Section 26-61a-102, providing pharmacy medical provider services in a

2376 medical cannabis pharmacy~~[-or]~~.

2377 ~~[(b) when acting as a state central patient portal medical provider, as that term is~~

2378 ~~defined in Section 26-61a-102, providing state central patient portal medical provider services.]~~

2379 (4) Notwithstanding Subsection (3), the division, in consultation with the board and in

2380 accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall define

2381 unprofessional conduct for a pharmacist described in Subsections (3)(a) and (b).

2382 Section 25. Section 58-67-502 is amended to read:

2383 **58-67-502. Unprofessional conduct.**

2384 (1) "Unprofessional conduct" includes, in addition to the definition in Section
2385 58-1-501:

2386 (a) using or employing the services of any individual to assist a licensee in any manner
2387 not in accordance with the generally recognized practices, standards, or ethics of the
2388 profession, state law, or division rule;

2389 (b) making a material misrepresentation regarding the qualifications for licensure under
2390 Section 58-67-302.7 or Section 58-67-302.8;

2391 (c) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
2392 Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;

2393 (d) violating the requirements of Title 26, Chapter 61a, Utah Medical Cannabis Act; or

2394 (e) falsely making an entry in, or altering, a medical record with the intent to conceal:

2395 (i) a wrongful or negligent act or omission of an individual licensed under this chapter
2396 or an individual under the direction or control of an individual licensed under this chapter; or

2397 (ii) conduct described in Subsections (1)(a) through (d) or Subsection 58-1-501(1).

2398 (2) "Unprofessional conduct" does not include:

2399 (a) in compliance with Section 58-85-103:

2400 (i) obtaining an investigational drug or investigational device;

2401 (ii) administering the investigational drug to an eligible patient; or

2402 (iii) treating an eligible patient with the investigational drug or investigational device;

2403 or

2404 (b) in accordance with Title 26, Chapter 61a, Utah Medical Cannabis Act:

2405 (i) when registered as a qualified medical provider or acting as a limited medical
2406 provider, as those terms are defined in Section 26-61a-102, recommending the use of medical
2407 cannabis; or

2408 (ii) when registered as a pharmacy medical provider, as that term is defined in Section
2409 26-61a-102, providing pharmacy medical provider services in a medical cannabis pharmacy[;
2410 ~~or~~].

2411 ~~[(iii) when registered as a state central patient portal medical provider, as that term is~~
2412 ~~defined in Section 26-61a-102, providing state central patient portal medical provider services.]~~

2413 (3) Notwithstanding Subsection (2)(b), the division, in consultation with the board and
2414 in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall define

2415 unprofessional conduct for a physician described in Subsection (2)(b).

2416 Section 26. Section **58-68-502** is amended to read:

2417 **58-68-502. Unprofessional conduct.**

2418 (1) "Unprofessional conduct" includes, in addition to the definition in Section

2419 **58-1-501**:

2420 (a) using or employing the services of any individual to assist a licensee in any manner
2421 not in accordance with the generally recognized practices, standards, or ethics of the
2422 profession, state law, or division rule;

2423 (b) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
2424 Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable;

2425 (c) making a material misrepresentation regarding the qualifications for licensure under
2426 Section **58-68-302.5**;

2427 (d) violating the requirements of Title 26, Chapter 61a, Utah Medical Cannabis Act; or

2428 (e) falsely making an entry in, or altering, a medical record with the intent to conceal:

2429 (i) a wrongful or negligent act or omission of an individual licensed under this chapter
2430 or an individual under the direction or control of an individual licensed under this chapter; or

2431 (ii) conduct described in Subsections (1)(a) through (d) or Subsection **58-1-501**(1).

2432 (2) "Unprofessional conduct" does not include:

2433 (a) in compliance with Section **58-85-103**:

2434 (i) obtaining an investigational drug or investigational device;

2435 (ii) administering the investigational drug to an eligible patient; or

2436 (iii) treating an eligible patient with the investigational drug or investigational device;

2437 or

2438 (b) in accordance with Title 26, Chapter 61a, Utah Medical Cannabis Act:

2439 (i) when registered as a qualified medical provider or acting as a limited medical
2440 provider, as those terms are defined in Section **26-61a-102**, recommending the use of medical
2441 cannabis; or

2442 (ii) when registered as a pharmacy medical provider, as that term is defined in Section
2443 **26-61a-102**, providing pharmacy medical provider services in a medical cannabis pharmacy[;
2444 ~~or~~].

2445 ~~[(iii) when registered as a state central patient portal medical provider, as that term is~~

defined in Section ~~26-61a-102~~, providing state central patient portal medical provider services.]

(3) Notwithstanding Subsection (2)(b), the division, in consultation with the board and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall define unprofessional conduct for a physician described in Subsection (2)(b).

Section 27. Section **78A-2-231** is amended to read:

78A-2-231. Consideration of lawful use or possession of medical cannabis.

(1) As used in this section:

(a) "Cannabis product" means the same as that term is defined in Section ~~26-61a-102~~.

(b) "Directions of use" means the same as that term is defined in Section ~~26-61a-102~~.

(c) "Dosing guidelines" means the same as that term is defined in Section ~~26-61a-102~~.

(d) "Medical cannabis" means the same as that term is defined in Section ~~26-61a-102~~.

(e) "Medical cannabis card" means the same as that term is defined in Section ~~26-61a-102~~.

(f) "Medical cannabis device" means the same as that term is defined in Section ~~26-61a-102~~.

(g) "Recommending medical provider" means the same as that term is defined in Section ~~26-61a-102~~.

(2) In any judicial proceeding in which a judge, panel, jury, or court commissioner makes a finding, determination, or otherwise considers an individual's medical cannabis card, medical cannabis recommendation from a recommending medical provider, or possession or use of medical cannabis, a cannabis product, or a medical cannabis device, the judge, panel, jury, or court commissioner may not consider or treat the individual's card, recommendation, possession, or use any differently than the lawful possession or use of any prescribed controlled substance if:

(a) the individual's possession complies with Title 4, Chapter 41a, Cannabis Production Establishments;

(b) the individual's possession or use complies with Subsection ~~58-37-3.7~~(2) or (3); or

(c) (i) the individual's possession or use complies with Title 26, Chapter 61a, Utah Medical Cannabis Act; and

(ii) the individual reasonably complies with the directions of use and dosing guidelines determined by the individual's recommending medical provider or through a consultation

described in Subsection 26-61a-502(4) [~~or (5)~~].

(3) Notwithstanding Sections 77-18-105 and 77-2a-3, for probation, release, a plea in abeyance agreement, a diversion agreement, or a tendered admission under Utah Rules of Juvenile Procedure, Rule 25, a term or condition may not require that an individual abstain from the use or possession of medical cannabis, a cannabis product, or a medical cannabis device, either directly or through a general prohibition on violating federal law, without an exception related to medical cannabis use, if the individual's use or possession complies with:

(a) Title 26, Chapter 61a, Utah Medical Cannabis Act; or

(b) Subsection 58-37-3.7(2) or (3).

Section 28. Section 80-3-110 is amended to read:

80-3-110. Consideration of cannabis during proceedings -- Drug testing.

(1) As used in this section:

(a) "Cannabis" means the same as that term is defined in Section 26-61a-102.

(b) "Cannabis product" means the same as that term is defined in Section 26-61a-102.

(c) (i) "Chronic" means repeated or patterned.

(ii) "Chronic" does not mean an isolated incident.

(d) "Directions of use" means the same as that term is defined in Section 26-61a-102.

(e) "Dosing guidelines" means the same as that term is defined in Section 26-61a-102.

(f) "Medical cannabis" means the same as that term is defined in Section 26-61a-102.

(g) "Medical cannabis cardholder" means the same as that term is defined in Section 26-61a-102.

(h) " Recommending medical provider" means the same as that term is defined in Section 26-61a-102.

(2) In a proceeding under this chapter, in which the juvenile court makes a finding, determination, or otherwise considers an individual's medical cannabis card, medical cannabis recommendation from a recommending medical provider, or possession or use of medical cannabis, a cannabis product, or a medical cannabis device, the juvenile court may not consider or treat the individual's medical cannabis card, recommendation, possession, or use any differently than the lawful possession or use of any prescribed controlled substance if:

(a) the individual's possession or use complies with Title 4, Chapter 41a, Cannabis Production Establishments;

2508 (b) the individual's possession or use complies with Subsection 58-37-3.7(2) or (3); or

2509 (c) (i) the individual's possession or use complies with Title 26, Chapter 61a, Utah

2510 Medical Cannabis Act; and

2511 (ii) the individual reasonably complies with the directions of use and dosing guidelines

2512 determined by the individual's recommending medical provider or through a consultation

2513 described in Subsection 26-61a-502(4) [~~or (5)~~].

2514 (3) In a proceeding under this chapter, a child's parent's or guardian's use of cannabis or

2515 a cannabis product is not abuse or neglect of the child unless there is evidence showing that:

2516 (a) the child is harmed because of the child's inhalation or ingestion of cannabis, or

2517 because of cannabis being introduced to the child's body in another manner; or

2518 (b) the child is at an unreasonable risk of harm because of chronic inhalation or

2519 ingestion of cannabis or chronic introduction of cannabis to the child's body in another manner.

2520 (4) Unless there is harm or an unreasonable risk of harm to the child as described in

2521 Subsection (3), in a child welfare proceeding under this chapter, a child's parent's or guardian's

2522 use of medical cannabis or a cannabis product is not contrary to the best interests of the child

2523 if:

2524 (a) for a medical cannabis cardholder after January 1, 2021, the parent's or guardian's

2525 possession or use complies with Title 26, Chapter 61a, Utah Medical Cannabis Act, and there

2526 is no evidence that the parent's or guardian's use of medical cannabis unreasonably deviates

2527 from the directions of use and dosing guidelines determined by the parent's or guardian's

2528 recommending medical provider or through a consultation described in Subsection

2529 26-61a-502(4) or (5); or

2530 (b) before January 1, 2021, the parent's or guardian's possession or use complies with

2531 Subsection 58-37-3.7(2) or (3).

2532 (5) Subsection (3) does not prohibit a finding of abuse or neglect of a child, and

2533 Subsection (3) does not prohibit a finding that a parent's or guardian's use of medical cannabis

2534 or a cannabis product is contrary to the best interests of a child, if there is evidence showing a

2535 nexus between the parent's or guardian's use of cannabis or a cannabis product and behavior

2536 that would separately constitute abuse or neglect of the child.

2537 (6) If an individual, who is party to a proceeding under this chapter, is ordered by the

2538 juvenile court to submit to drug testing, or is referred by the division or a guardian ad litem for

drug testing, the individual may not be ordered or referred for drug testing by means of a hair or fingernail test that is administered to detect the presence of drugs.

Section 29. Section **80-4-109** is amended to read:

80-4-109. Consideration of cannabis during proceedings.

(1) As used in this section:

(a) "Cannabis" means the same as that term is defined in Section 26-61a-102.

(b) "Cannabis product" means the same as that term is defined in Section 26-61a-102.

(c) (i) "Chronic" means repeated or patterned.

(ii) "Chronic" does not mean an isolated incident.

(d) "Directions of use" means the same as that term is defined in Section 26-61a-102.

(e) "Dosing guidelines" means the same as that term is defined in Section 26-61a-102.

(f) "Medical cannabis" means the same as that term is defined in Section 26-61a-102.

(g) "Medical cannabis cardholder" means the same as that term is defined in Section 26-61a-102.

(h) "Qualified medical provider" means the same as that term is defined in Section 26-61a-102.

(2) In a proceeding under this chapter in which the juvenile court makes a finding, determination, or otherwise considers an individual's possession or use of medical cannabis, a cannabis product, or a medical cannabis device, the juvenile court may not consider or treat the individual's possession or use any differently than the lawful possession or use of any prescribed controlled substance if:

(a) the individual's possession or use complies with Title 4, Chapter 41a, Cannabis Production Establishments;

(b) the individual's possession or use complies with Subsection 58-37-3.7(2) or (3); or

(c) (i) the individual's possession or use complies with Title 26, Chapter 61a, Utah Medical Cannabis Act; and

(ii) the individual reasonably complies with the directions of use and dosing guidelines determined by the individual's qualified medical provider or through a consultation described in Subsection 26-61a-502(4) [~~or (5)~~].

(3) In a proceeding under this chapter, a parent's or guardian's use of cannabis or a cannabis product is not abuse or neglect of a child unless there is evidence showing that:

(a) the child is harmed because of the child's inhalation or ingestion of cannabis, or because of cannabis being introduced to the child's body in another manner; or

(b) the child is at an unreasonable risk of harm because of chronic inhalation or ingestion of cannabis or chronic introduction of cannabis to the child's body in another manner.

(4) Unless there is harm or an unreasonable risk of harm to the child as described in Subsection (3), a parent's or guardian's use of medical cannabis or a cannabis product is not contrary to the best interests of a child if:

(a) for a medical cannabis cardholder after January 1, 2021, the parent's or guardian's possession or use complies with Title 26, Chapter 61a, Utah Medical Cannabis Act, and there is no evidence that the parent's or guardian's use of medical cannabis unreasonably deviates from the directions of use and dosing guidelines determined by the parent's or guardian's qualified medical provider or through a consultation described in Subsection 26-61a-502(4) or (5); or

(b) before January 1, 2021, the parent's or guardian's possession or use complies with Subsection 58-37-3.7(2) or (3).

(5) Subsection (3) does not prohibit a finding of abuse or neglect of a child and Subsection (3) does not prohibit a finding that a parent's or guardian's use of medical cannabis or a cannabis product is contrary to the best interests of a child, if there is evidence showing a nexus between the parent's or guardian's use of cannabis or a cannabis product and behavior that would separately constitute abuse or neglect of the child.

Section 30. **Repealer.**

This bill repeals:

Section 26-61a-602, State central patient portal medical provider.